Adoptive T-cell therapy for Leukemia.

Introduction

T-lymphocytes are critical cells of the immune system that eliminate both infectious pathogens and abnormal, malignant cells. The importance of T-cells in the elimination of leukemia was first supported by trials comparing T-cell replete versus T-cell depleted allogeneic stem cell transplant (alloSCT), where a higher incidence of disease relapse was observed for recipients of T-cell depleted transplants, but with the advantage of a lower incidence of graft-versus-host disease (GvHD) [ 1 – 6 ]. The data for this effect are strongest in chronic myeloid leukemia (CML), though evidence for T-lymphocyte targeting of malignant cells within other leukemia diagnoses – acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL) - also comes from trials demonstrating success with donor lymphocyte infusion (DLI) for relapsed leukemia after alloSCT [ 7 – 11 ]. DLI is a treatment comprised of unselected, polyclonal donor lymphocytes and is frequently administered in the absence of preparative conditioning. It provides the most direct proof of the potent graft-versus-leukemia (GvL) effect mediated by allogeneic T-cells, but GvHD complicates DLI in up to 60% of patients [ 12 ]. Thus, adoptive cellular therapy (ACT) has arisen from the desire to isolate and enhance the GvL effect that accounts for the efficacy of alloSCT and DLI while minimizing GvHD toxicity, which causes significant morbidity and mortality. ACT is a type of cancer treatment that involves infusing patients with large numbers of autologous or allogeneic lymphocytes that have undergone ex vivo selection and modification. The goal of ACT for leukemia is to administer T-cells that target leukemia antigens with minimal impact on normal tissues.

It is important to highlight that GvL and GvHD both refer to the allogeneic setting where donor T-cells are presumed to recognize both tumor-associated antigens (nonpolymorphic self antigens that are overexpressed in malignant cells), minor histocompatibility antigens (polymorphic host antigens that are foreign to the donor) and tumor-specific antigens (antigens that are mutated or solely expressed by the tumor cell) [ 13 , 14 ]. Graft-versus-tumor effects are not exclusive to allogeneic T-cells, however, and Rosenberg et al. have pioneered efforts to use a patient’s autologous T-cells to combat melanoma, and more recently carcinoma, using several strategies with much success [ 15 , 16 ]. With regard to hematologic disease, using ACT is a natural extension of standard of care approaches that are currently employed to treat leukemia, lymphoma, and myeloma - specifically autologous and alloSCT. Limiting this approach, though, are a lack of known tumor antigens and mechanisms of central and peripheral T-cell tolerance whereby T-cells with high affinity for self-antigens are deleted in the thymus or are rendered hyporesponsive through various mechanisms that can be exploited by the immunosuppressive tumor microenvironment [ 17 ]. Numerous high throughput methodologies are being explored for the identification of novel tumor antigens, and, to bypass T-cell tolerance, research is now capitalizing on advances made in synthetic biology and basic immunology to engineer and redirect T-cells to eliminate tumor cells. The purpose of this review is to provide an overview of various strategies being developed to improve the adoptive transfer of T-cells for immunotherapy of leukemia, with a focus on the approaches being tested in clinical trials.

Review

Leukemia antigens

Arguably, the most important aspect of ACT is the targeted antigen, and this is becoming increasingly true as methods to enhance the T-cell receptor (TCR) affinity and to lower T-cell activation thresholds are incorporated. These improvements narrow the therapeutic window for ACT and necessitate careful antigen selection. Many, but not all, tumor antigens arise from intracellular proteins that must be processed and presented by a cell’s major histocompatibility complex (MHC) in order to trigger TCR-binding and provoke an immune response. In contrast, the implementation of chimeric antigen receptors (CARs) has now broadened the pool of potential antigens to include extracellular, non-MHC bound molecules. The ideal tumor antigen is expressed on all malignant cells including cancer stem cells, demonstrates high immunogenicity, is absent in normal tissue, and derives from a protein required for maintenance of the malignant phenotype, which prevents a leukemic subclone from escaping T-cell detection by downregulating the antigen’s expression [ 18 ].

There are several classes of tumor antigens (Table 1 ). Many are tumor-associated antigens (TAAs) derived from self-proteins that are expressed at low levels in normal tissue and overexpressed or aberrantly expressed in malignant cells, such as Wilms tumor-1 (WT-1) [ 19 ]. Tumor differentiation antigens are a subset of TAAs that arise from self-proteins and are expressed in a distinct subset of normal cells and often at higher levels in their malignant cell counterpart. PR1, a peptide from neutrophil elastase and proteinase 3, is an example of a tumor differentiation antigen as its source proteins are induced during the promyelocyte stage and are overexpressed in myeloid leukemias [ 20 – 22 ]. Targeting these classes of self-antigens has shown promise in preclinical models, vaccine trials, and early adoptive T-cell trials, but risks toxicity to normal tissues as the antigens are not strictly found on malignant cells. This is also true for the cancer-testis antigens, a family of proteins expressed primarily by germ cells and in various malignancies [ 23 ]. Several recent trials highlight the risks of targeting TAAs, including a trial at the National Institutes of Health (NIH) that tested the adoptive transfer of autologous T-cells engineered to express a murine TCR with specificity for an HLA-A2-restricted peptide from carcinoembryonic antigen (CEA) [ 24 ]. Anti-CEA T-cells were administered to 3 patients with metastatic colon cancer. The treatment caused tumor regression, including 1 partial response (PR), but severe, dose-limiting toxicity in the form of inflammatory colitis was observed in all patients and caused the trial to be halted. The colitis was an on-target adverse effect resulting from T-cells recognizing the CEA epitope on normal colonic epithelium, illustrating that the targeting of self-antigens with modified T-cells is not without consequence. Table 1 Classes of Leukemia Antigens Leukemia antigens Class Example(s) Pros Cons Tumor-associated antigens (TAAs) WT-1 [ 25 ], hTERT [ 26 ], PRAME [ 27 ], HMMR/Rhamm [ 28 ] - multiple candidates identified- often shared by > 1 malignancy - present on normal tissue - self antigens that generate low-avidity T-cells- must be successfully processed and presented by the MHC of the malignant cell Tumor differentiation antigens PR1 [ 29 ], CG1 [ 30 ], CD33 [ 31 ] - more restricted distribution than TAAs - present on subset of normal cells, which can include hematopoietic stem cells Cancer testis (CT) antigens Cyclin-A1 [ 32 ], NY-ESO-1 [ 33 ] , MAGE [ 34 ] - frequently restricted to non-essential tissues and tumor - few identified in leukemia Minor histocompatibility antigens (mHAs) HA-1 [ 35 ], ACC1 [ 36 ], T4A [ 37 ], LB-LY75-IK [ 38 ] - result in high avidity allo T-cells since epitopes are foreign to donor- some are largely restricted to hematopoietic compartment - Necessitate rescue with mHA-negative stem cells to restore normal hematopoiesis- need for allogeneic TCRs - must be successfully processed and presented by the MHC Tumor-specific antigens (neoantigens) BCR-ABL [ 39 ], FLT3-ITD [ 40 ], B-cell receptor idiotype [ 41 ] - result in high avidity autologous T-cells- many derive from proteins critical in leukomogenesis - individual-specific- few identified in leukemia since mutation rate is low Oncoviral antigens HTLV-I Tax protein [ 42 ] - generate very high-avidity T-cells - only relevant to virus-initiated malignancies Extracellular antigens CD19 (see CD19 section), Lewis Y [ 43 ], CD22 [ 44 ], ROR1 [ 45 ] -MHC-independent - interaction with CAR is high-affinity - many are present on normal tissues - require CAR for targeting , which can mediate on-target, off-tumor adverse effects Additional references added in the table [ 31 – 34 , 36 – 38 , 40 , 45 ].

In the allogeneic setting, minor histocompatibility antigens (mHAs) are endogenous polymorphic proteins that differ between donor and recipient and can serve as targets for GvL and GvHD [ 13 ]. These represent important antigens because donor cells are not tolerized to these ‘foreign’ peptides enabling them to elicit higher avidity T-cell responses. One goal is to identify mHAs that are confined to the hematopoietic compartment, because in this scenario, after the host blood system is replaced with donor cells by alloSCT, the only mHA-expressing cells remaining are malignant host cells. At least 12 such hematopoietic-predominant mHAs have been identified thus far and one such antigen, HA-1, has been targeted in a pilot clinical trial [ 35 , 46 ].

Also in the category of "non-self" antigens are neoantigens, otherwise known as tumor-specific antigens. These are novel peptides that result from chromosomal translocations, point mutations, deletions, or insertions within a malignant cell’s genome. Neoantigens theoretically represent ideal targets as they should elicit high avidity T-cells, they are absent on normal cells, and they may originate from "driver" genes that are leukemogenic. In melanoma, a highly mutated disease, it is thought that neoantigens constitute much of the anti-tumor immune response [ 47 – 49 ]. Leukemias, however, are among cancers with the lowest mutation rate, making such antigens difficult to identify [ 50 , 51 ]. In CML, the BCR-ABL translocation does represent one source for leukemic neoantigens, and several epitopes from this fusion protein have been shown to elicit a T-cell response [ 52 – 55 ]. Early trials of adoptively transferred anti-BCR-ABL T-cells have proven safe with some evidence of disease response, however, the success of tyrosine kinase inhibitors in CML has largely overshadowed the development of ACT for this disease [ 56 , 57 ].

Tumor-specific antigens (neoantigens) can also be found within the clonal idiotypes unique to B-cell malignancies, which contain the variable regions of the B-cell receptor immunoglobulin heavy and light chains [ 58 ]. Vaccination strategies against these epitopes have demonstrated success in lymphoma [ 41 ]. These antigens are patient-specific, though, which raises questions about the feasibility of using these epitopes and other highly individualized neoantigens as targets. With advances in whole exome sequencing and T-cell engineering, though, they will likely gain importance.

The last class of "non-self" intracellular antigens are oncoviral peptides, which are being investigated as immunotherapeutic targets in human papillomavirus-initiated cervical cancer, Epstein Barr Virus (EBV)-related post-alloSCT B-cell lymphoproliferative disease, and EBV-associated lymphomas [ 59 – 61 ]. They may also be applicable in the setting of virally-induced hematologic malignancies, such as HTLV-1 associated T-cell leukemia/lymphoma [ 42 , 62 ]. The advantage of these viral peptides is that they elicit very high avidity T-cell responses in contrast to endogenous human epitopes [ 63 ].

Finally, it is important to emphasize that all of the tumor antigens discussed thus far are intracellular antigens, which rely on intact, functional cellular machinery for their processing and MHC-restricted presentation. This is a fundamental limitation of TCR-based T-cell therapy because human leukocyte antigen (HLA) subtypes are highly polymorphic and labor-intensive strategies that target a single epitope will only apply to the subset of patients expressing that particular HLA allele. Furthermore, malignant cells are known to evade the immune system by altering antigen processing and downregulating their MHC expression [ 64 ]. One strategy to bypass these constraints is through use of CAR T-cells that target broadly expressed membrane-bound molecules. A CAR links a portion of the antibody binding domain to T-cell costimulatory and signaling domains [ 65 ]. Because the recognition domain is engineered from an immunoglobulin, the CAR recognizes extracellular, membrane-bound epitopes that are not confined to an MHC, and this groundbreaking development has added a new class of leukemia antigens and vastly expanded the number of targetable epitopes. Dozens of extracellular molecules are now being investigated for their value as tumor antigens and, in leukemia, these include CD19, CD20, CD22, CD30, Lewis Y antigen, among others [ 66 ]. However, although the immune response can be effectively engineered using this technology, the antigens that CAR T-cells target must still be evaluated for their expression in normal tissues and for their importance in leukemogenesis to limit the possibility of selecting for antigen escape variants. Lastly, even though the majority of CAR T-cells developed to date have targeted broadly expressed cell surface receptors, CAR T-cells that target peptides presented on HLA molecules are also currently being investigated and work by integrating TCR-mimicking antibodies [ 67 ]. It is likely that successful immunotherapy for leukemia will require targeting many of these antigens in multiple pathways, which likely accounts for the success of the graft-versus-leukemia effect.

Adoptive T-cell Transfer Strategies for Leukemia

Although this review focuses specifically on modifications and ex vivo manipulation of CD4+ and CD8+ αβ T-lymphocytes for adoptive transfer and treatment of leukemia, ACT using other effector cell types – including γδ T-cells, natural killer (NK) cells, NK T-cells, and invariant NK T cells - is also an area of active investigation [ 68 – 71 ]. Adoptive T-cell therapy represents a natural extension of current treatment for leukemia because allogeneic transplant and DLI already involve the transfer of large numbers of T lymphocytes. Further, adoptive T-cell transfer to prevent CMV, adenovirus, and Aspergillus infections in the context of alloSCT has been well studied and provides a valuable foundation for T-cell transfer strategies [ 72 – 78 ]. T-cells have many properties of an ideal therapeutic - their area of biodistribution is broad and includes the central nervous system, they can expand and increase their potency in vivo , and they can acquire long half-lives by establishing memory, ideally providing a reservoir of antitumor immunity that leads to actual cancer cures [ 79 , 80 ].

There are numerous strategies being developed to target malignant cells via adoptive T-cell transfer (Figure 1 ). A major division within current ACT approaches is whether or not T-cells undergo genetic modification prior to infusion. T-cells that do not undergo this additional step (conventional T-cells) must undergo ex vivo manipulation and expansion prior to administration, an extensive process where cells may spend a month or more in culture. The goal of this step is to generate large numbers of T-cells that are specific for one or more tumor antigens from an infrequent and polyclonal population. In contrast, genetic modification of T-cells bypasses these lengthy enrichment protocols by direct transfer of either TCR α and β chains or a CAR, thereby endowing lymphocytes with a secondary, engineered specificity. The rationale, advantages, and disadvantages for the most common strategies are presented here. Figure 1 Graphic representations of the various T-cell approaches used to target leukemia antigens. (a) Conventional T-cells target peptides that are presented in the context of an MHC molecule. (b) Modified Ectopic α/β T-cells target the same epitope as a conventional TCR (MHC-peptide) but with an engineered (often higher affinity) TCR from an autologous, allogeneic, or xenogeneic cell. (c) CAR T-cells contain a synthetic polypeptide that contains the single chain variable fragment (scFv) of an antibody as the antigen-binding domain, a hinge, a transmembrane region, a costimulatory (Costim) domain, and a CD3ζ signaling domain. CARs recognize extracellular antigens that are not MHC-bound. (d) A TCR-like CAR utilizes the scFv fragment of a TCR-mimicking Ab, which recognizes a peptide antigen in the context of an MHC molecule, but with a much higher affinity than conventional or most engineered TCRs.

Transfer of unmodified, conventional T-cells includes both autologous and allogeneic lymphocytes that range in antigen specificity from polyclonal populations to antigen-enriched subsets to antigen-specific T-cell clones. Transfer of allogeneic polyclonal T-cells describes a DLI, which can be effective for treating relapsed leukemia after alloSCT though with a high risk of GvHD [ 12 ]. Adoptive transfer of bulk, ex vivo activated, autologous polyclonal lymphocytes has been tested by Rapoport et al. and, when administered with tumor vaccines, can generate antitumor immunity [ 81 ]. However, both central and peripheral tolerance hinder this approach and T-cells with specificity for tumor antigens are infrequent, have low avidity, and can be rendered anergic by the immunosuppressive tumor microenvironment [ 17 , 63 ]. A number of tumor-specific T-cell enrichment strategies exist and include culturing lymphocytes in the presence of irradiated tumor cells, stimulating mHA-naive allogeneic T-cells in the presence of mHA-positive host antigen-presenting cells (APCs), or extracting T-cells from tumor specimens and subsequently expanding them for reinfusion. For example, a recent trial at the NIH tested the adoptive transfer of polyclonal tumor-derived lymphocytes for the treatment of relapsed CLL or lymphoma after alloSCT [ 82 ]. The rationale underlying this approach is that T-cells found within tumor specimens are enriched for tumor antigen-specific cytotoxic T-lymphocytes (CTLs), which can be made more potent by ex vivo costimulation and expansion. This is analogous to tumor-infiltrating lymphocyte (TIL) therapy for melanoma, which has demonstrated overall response rates of up to 72% [ 83 ]. In the lymphoma/CLL trial, 8 patients were treated with lymphocytes that were first extracted from their tumor biopsy specimens and subsequently activated and expanded with anti-CD3/anti-CD28 Ab-coated magnetic beads. No GvHD was observed and modest anti-tumor activity was seen in 4 patients [ 82 ]. Additionally, towards the goal of targeting multiple antigens simultaneously, a recent study demonstrated that autologous, functional T cells from ALL patients could be generated with specificities enriched for multiple TAA (PRAME, WT-1, MAGE-A3, and Survivin) by stimulating lymphocytes using autologous APCs pulsed with complete peptide pools spanning the entire amino acid sequences of the tumor-associated proteins [ 84 ].

The most precise approach using conventional T-cells is transfer of antigen-specific CTL clones, which are generated by labor-intensive limiting dilution cloning techniques [ 85 ]. These methods produce large numbers of monoclonal T-cells that recognize a defined HLA-restricted tumor epitope. Autologous or allogeneic CTL clones can be generated using a variety of stimulator cells. For example, large numbers of CTL clones with specificity for an immunodominant HLA-A2-restricted epitope from WT-1 were generated by stimulating donor T-cells repeatedly with peptide-pulsed autologous DCs for use in a recent clinical trial (discussed below) [ 25 ]. There are benefits to using conventional T-cells over T-cells genetically engineered to express an ectopic TCR α and β chain. With conventional T-cells, there are no concerns for ectopic and endogenous TCR α/β mispairing, which has the potential to generate new specificities and cause harm by nonspecifically reacting with normal tissues [ 86 ]. Also, though viral transduction of TCRs into mature cells has thus far proven safe, the use of conventional T-cells also eliminates the worry for insertional oncogenesis of transduced lymphocytes [ 87 , 88 ]. Additionally, with conventional allogeneic CTL clones, there is no secondary specificity of the T-cells and thus a much lower risk for off-target GvHD. Finally, conventional T-cells – whether autologous or allogeneic – have been educated in the human thymus and have toxicities that are more predictable than those for murine TCRs and affinity-enhanced TCRs, which have exhibited deleterious off-target effects [ 89 ]. On the other hand, the efficacy of adoptive transfer of conventional T-cells is limited by several factors. Tumor antigen-specific T-cells, particularly those that recognize "self" antigens, are generally of low avidity - a problem that can be exacerbated in patients with leukemia [ 90 ]. Moreover, generating large numbers of clones requires weeks of repetitive stimulation in culture, which can further reduce T-cell avidity while allowing time for tumors to progress. Similarly, extensive ex vivo manipulation can select for T-cells with more differentiated, exhausted effector phenotypes that are less likely to mediate durable, potent tumor regression after adoptive transfer [ 91 ].

To bypass many of these limitations, methods have been developed to deliver the genes for full-length TCR α and β chains into autologous or allogeneic peripheral blood mononuclear cells (PBMC), creating bispecific T-cells with specificities determined by both the cell’s endogenous TCR and the engineered TCR [ 92 ]. This approach dramatically shortens the ex vivo manipulation process and allows for generation of high avidity clones. This strategy also allows for pre-selection of a desired subset of lymphocytes for TCR transduction (central memory T-cells, stem cell memory T-cells, etc.), which have demonstrated better persistence and expansion in vivo relative to the terminally differentiated, effector lymphocytes often generated by lengthy limiting dilution cloning protocols [ 93 – 96 ]. Retroviruses, lentiviruses, transposons, and other constructs are all being actively investigated as means to deliver the TCR (or CAR – see below), and the pros and cons of each of these methods are outside the scope of this discussion but have been reviewed by others [ 97 , 98 ]. Many refinements to TCR-engineering protocols have already been developed and include the addition of disulfide bonds to prevent TCR α/β mispairing and codon optimization to facilitate better TCR expression [ 99 , 100 ]. Additionally, very high affinity xenogeneic TCRs from HLA-A2 transgenic mice can be transferred into human PBMC using these methods [ 101 – 104 ]. TCR affinity can be further enhanced via site-directed mutagenesis of the TCR antigen-binding region [ 105 ]. Unfortunately, some of these "supercharged" T-cells have demonstrated unpredictable toxicities in patients, and new safety measures for testing high-affinity, modified T-cells against human tissue samples prior to their use in clinical trials will need to be implemented [ 89 , 106 , 107 ]. Nevertheless, several TCR constructs derived from conventional, human T-cells with physiologic avidities have undergone extensive preclinical testing and will now be studied in human leukemia trials including those that redirect T-cells against HLA-A2 restricted epitopes of HA-1 and WT-1 [ 100 , 108 ]. One potential drawback to all types of TCR-based ACT is that the binding between the TCR and MHC/peptide complex is inherently degenerate, meaning that a given TCR can recognize more than 1 peptide-MHC ligand [ 109 ]. This could result in unforeseen toxicity in the form of off-target tissue effects, particularly when large numbers of cells with affinity enhanced or xenogeneic TCRs are infused. Lastly, though ectopic TCR transfer overcomes many of the limitations posed by conventional T-cells, the targeted epitopes must still be successfully processed within the proteasome and subsequently presented in the context of an MHC molecule, which may afford malignant cells the opportunity to escape this therapy via downregulation of surface MHC or aberrant antigen processing.

As alluded to above, CARs represent a unique strategy designed to circumvent many drawbacks of TCR-based ACT. The antigen-recognition domain of the CAR is derived from an antibody’s single-chain variable fragment (scFv), which recognizes epitopes within membrane-bound molecules. The majority of CARs developed to date target broadly expressed surface molecules that are independent of MHC, though CARs can be engineered to recognize peptide-HLA epitopes as well [ 67 ]. The scFv fragment is linked to a transmembrane region, a signaling protein (typically CD3ζ), and a costimulatory domain (CD28, 4-1BB, OX-40, ICOS, and others). The CARs are delivered using vehicles similar to those discussed above for ectopic TCRs (lentiviruses, retroviruses, etc.). CARs were first reported by Gross et al. in 1989 [ 65 ]. Early clinical trials using CARs demonstrated disappointing efficacy, largely due to the lack of persistence of the modified cells [ 110 – 112 ]. These 1 st generation CARs lacked a costimulatory domain. The addition of a costimulatory domain (initially CD28 or 4-1BB) has revolutionized the field and these 2 nd generation CARs have begun to demonstrate impressive clinical responses, particularly using anti-CD19 CARs for treatment of B-cell malignancies (see CD19 section below). Now, 3 rd generation CARs (those with >1 engineered costimulatory domain) are reaching clinical testing and may further enhance the redirected T-cells’ activity. By targeting extracellular epitopes, CARs have the distinct advantage of thwarting many mechanisms of tumor immunoevasion including MHC downregulation and altered protein processing. The problem of tumor escape is not solved completely, however, and malignant cells with little or no expression of the targeted antigen may evade this approach, underscoring the importance of targeting proteins that are critical in leukemogenesis [ 79 ]. Another important advantage of CARs is that they are very high-affinity receptors that mediate eradication of malignant cells with low levels of antigen expression. A consequence of this enhanced affinity is that normal cells with low antigen expression will also be targeted resulting in increased on-target, off-tissue adverse effects [ 24 , 113 , 114 ]. CAR and ectopic TCR approaches share many of the same advantages over conventional T-cell ACT. For example, the subset of T-cells to be transduced with either artificial receptor can be pre-enriched for central memory T-cells, stem cell memory T-cells, or virus-specific T-cells and either allogeneic or autologous cells can be used for transduction. A fundamental difference between CARs and ectopic TCRs is that they target extracellular or intracellular antigens, respectively, but even this line is being blurred. TCR-mimicking antibodies against PR1 and WT-1 have been generated and are now being tested in TCR-like CAR constructs in preclinical mouse models [ 67 , 115 , 116 ]. These receptors function like TCRs since they recognize a peptide antigen in the context of an MHC molecule, but they have the benefit of binding with higher affinity than a TCR. These and other recent advances illustrate how the field of ACT is rapidly evolving, and it is likely that genetically modified T-cells will overtake conventional T-cells within the field of ACT.

Additional T-cell modifications

Specificity is not the only focus of T-cell engineering. Though outside the scope of this review, other authors have outlined the many ways by which researchers are aiming to build a better T-cell [ 66 , 97 , 117 – 119 ]. Examples of these strategies include incorporating additional chemokines to improve T-cell trafficking, artificially upregulating anti-apoptotic proteins, increasing resistance to immunosuppressive cytokines, and adding suicide genes to delete the modified lymphocytes in the event of significant toxicity [ 120 – 126 ].

Allogeneic SCT platform

In many ways, ACT for leukemia lends itself to the allogeneic SCT setting where large numbers of allogeneic T-cells are infused along with CD34+ progenitor cells after conditioning chemotherapy. ACT is not limited to this setting, however, and anti-CD19 CAR therapy in the absence of transplant and in the autologous setting has demonstrated success in heavily pretreated and refractory CLL patients [ 80 ]. Many questions will need to be answered to utilize ACT most effectively and to properly position it alongside current treatments including cytotoxic chemotherapy, molecular-targeted agents, and alloSCT (Figure 2 ). Cost and manufacturing capabilities will undoubtedly factor into these decisions as well. It is conceivable that ACT could become initial, first-line therapy for certain leukemia subtypes in contrast to the challenging, post-alloSCT relapse setting where it is typically tested today. Moreover, progress continues to be made in other types of therapy making treatment decisions a moving target. For example, alloSCT has historically been reserved for young, healthy patients with relapsed or high-risk disease, but this is changing with the advent of nonmyeloablative transplant and improved supportive care [ 127 , 128 ]. Figure 2 Diagram of ACT within the alloSCT platform. T-cell depleted SCT would eliminate the need for post-SCT immunosuppressive medications that can limit the efficacy of modified T-cells. Since allogeneic cells are used, the endogenous specificity of the T-cells would be pre-selected (CMV, EBV, varicella, etc.) or other GvHD prevention measures would need to be incorporated, such as naïve T cell depletion.

One aspect of ACT that is established and relevant to leukemia is the benefit achieved with lymphodepletion. This has been studied in the non-transplant setting where depleting host lymphocytes prior to adoptive T-cell transfer improves T-cell expansion and persistence by freeing up important cytokines (IL-7, IL-15), encouraging homeostatic peripheral expansion, and depleting regulatory T-cells [ 129 – 133 ]. Conditioning chemotherapy prior to alloSCT would then serve a dual purpose in this setting – eradication of disease and creation of space for transferred leukemia-specific T-cells. Additionally, it may be advantageous for patients to be in a state of minimal residual disease (MRD) at the time of ACT, which is often the situation after alloSCT. This may be especially true for aggressive malignancies like AML and ALL, where the leukemia burden can quickly increase. The reasons for this are two-fold: first, it has been observed in early clinical trials that ACT-associated toxicities such as the cytokine-release syndrome are more severe in patients with larger disease burdens and second, it can take days to weeks for modified T-cells to expand in vivo and so an MRD state affords the modified T-cells time to proliferate and potentially overtake the malignant cell population. Unfortunately, it is not always possible for patients to reach a state of MRD, and early trials have shown that anti-CD19 CAR therapy can mediate dramatic leukemia responses even in patients with very advanced disease, proving its versatility [ 79 , 134 , 135 ].

Two main concerns will need to be addressed to successfully apply ACT to the alloSCT setting: the potential for triggering GvHD and interference caused by immunosuppressive medications. Since the recipient’s hematopoietic system is replaced by donor cells after alloSCT, conventional or modified adoptively transferred T-lymphocytes will need to be of donor origin. This being said, in the future it may be possible to use universal or 3 rd party donor T-cells by incorporating zinc-finger nuclease technology that can be used to knockdown a T-cell’s MHC class I/II expression as well as its endogenous TCR [ 136 ]. Nevertheless, it is well established that infusing large numbers of allogeneic T-cells into patients shortly after transplant results in unacceptable rates and severity of GvHD [ 137 ]. Therefore, it will not be possible to simply transduce bulk donor T-cells with the desired antigen-specific TCR or CAR construct and infuse these cells at the time of transplant since the endogenous allogeneic polyclonal TCRs would trigger GvHD. This problem can be approached from many angles. One possibility is to isolate donor lymphocytes with defined, known specificities (EBV, CMV, varicella, etc.) and to subsequently transduce only these oligoclonal T-cells with a synthetic receptor (CAR or ectopic TCR) and then infuse them at the time of transplant [ 138 , 139 ]. Another option is to deplete naïve donor T-cells prior to ex vivo TCR/CAR transduction since naive T-cells have been shown to play an important role in GvHD [ 140 – 142 ]. In contrast, if bulk polyclonal donor cells are used, delayed, low-dose administration of ACT at time of relapse or many months after alloSCT may mitigate GvHD. This is based on trials of DLI, where administration of low dose donor T-cells more than 9 months after transplant resulted in a GvHD rate of only 10% [ 143 , 144 ]. Encouragingly and along these same lines, in early trials of anti-CD19 CAR therapy, infusions of modified, polyclonal donor-derived cells that were collected from the recipient (post-transplant) did not cause GvHD, possibly because of tolerance developed within the host [ 145 , 146 ].

A separate platform for ACT that should be considered is T-cell depleted alloSCT. Though opportunistic infections would be expected to increase, this approach might be advantageous because it would eliminate the need for immunosuppressive agents, which are known to abrogate the effects of adoptively transferred T-cells [ 134 , 135 ]. Otherwise, for T-cell replete alloSCT, an attractive strategy is to arm modified, antigen-specific T-cells with resistance to immunosuppressive drugs (calcineurin inhibitors, mycophenolate mofetil, methotrexate, or glucocorticoids) [ 46 , 147 – 149 ]. Still, it must be kept in mind that the rationale for using allogeneic rather than autologous transplants for leukemia is both to avoid infusion of malignant cells and to harness the GvL effect. If the GvL effect is successfully condensed to a handful of tumor antigens, then tumor-restricted, antigen-specific TCR and/or CAR constructs could be developed to target these antigens. This would permit the use of autologous grafts and autologous ACT (minor histocompatibility antigens excluded), which could significantly reduce (if not eliminate) GvHD. As outlined, the rapid pace of discovery in the field of ACT is exciting. Developing the most effective ACT will require careful consideration of the optimal antigens to target (likely in combination), the T-cell approach to utilize, and which of the myriad additional modifications to incorporate into the engineered lymphocytes.

Challenges and limitations

Though immunotherapy is typically characterized as less toxic and more specific than chemotherapy and other cancer therapies, multiple serious adverse effects in early clinical trials using ACT underscore its tremendous potency and risks. Adverse effects have resulted from multiple mechanisms. On-target, off-tissue toxicity describes the situation where a T-cell appropriately recognizes an antigen of interest (via TCR or CAR), but in the case where this antigen is also expressed on healthy tissues. One example of on-target, off-tissue toxicity was reported in a Phase I clinical trial of renal cell carcinoma patients treated with autologous CAR T-cells engineered to recognize an epitope within the carbonic anhydrase IX (CAIX) tumor-associated protein [ 113 ]. Multiple patients experienced significant liver toxicity due to the expression of CAIX on normal bile duct epithelium requiring cessation of treatment in 4 patients. This on-target, off-tissue toxicity can be mediated either by a CAR or a TCR, however, CAR T-cells may prove the worst offenders because of their inherent high affinity and built-in costimulation. Off-target toxicity occurs when the antigen receptor (CAR or TCR) recognizes a different epitope than is intended. This form of toxicity has been more common with TCRs, which are inherently degenerate, and particularly with mutated and xenogeneic TCRs that bypass education in the thymus and can have unpredictable specificities. For example, a patient-derived TCR with specificity for the cancer-testis antigen HLA-A*01-MAGE-A3 first underwent site-directed mutagenesis resulting in enhanced affinity of the receptor, was subsequently incorporated into a lentiviral vector, and was then used in a clinical trial testing the construct against myeloma and melanoma. Unfortunately, the first 2 patients treated experienced fatal cardiac toxicity that was incited by an off-target epitope within the normal cardiac myocyte protein titin (off-target titin peptide: ESDPIVAQY; on-target MAGE-A3 peptide: EVDPIGHLY) [ 89 , 106 ]. These adverse events have since been carefully analyzed and have generated much discussion about strategies to predict on and off-target toxicity.

Issues of specificity and antigen selection are paramount to the success of ACT but other challenges remain. Even in the context of a highly avid T-cell and a tumor-restricted antigen, T-cell persistence, trafficking, and diminishing receptor transgene expression can all be problematic [ 150 ]. Furthermore, the tumor microenvironment is an inhospitable place for T-cells and adoptively transferred cells will need to resist inhibitory signals from tumor and stromal cells to remain effective [ 151 ]. Even after initial recognition and lysis of tumor cells, the adoptively transferred lymphocytes must then outcompete the tendency of malignant subclones to evade killing via downregulation of MHC molecules, altered antigen processing, and epigenomic and genomic evolution [ 64 ]. And on a broader scale, issues of cost, manufacturing, and standardization will also be important to the applicability of ACT and have been reviewed by others [ 97 , 152 ]. Finally, even patients who experience durable, complete remissions from ACT can experience adverse effects in the form of cytokine release syndrome, tumor lysis syndrome, hemophagocytic lymphohistiocytosis, and B-cell aplasia though investigators and clinicians are learning a great deal about how to limit these toxicities. It must be kept in mind, though, that many of the patients treated with ACT thus far have dismal prognoses and limited to no treatment options in the absence of clinical trials. Furthermore, ACT is still in its infancy and if the current pace of innovation is sustained, it promises to grow in importance. Along these lines, below is a discussion of current strategies being tested in clinical trials.

Targeting leukemia antigens in the clinic

CD19

Trials of anti-CD19 CAR T-cell therapy in patients with B-cell malignancies have generated exciting clinical results and underscore the tremendous potential of antigen-specific ACT for leukemia. These trials – spearheaded by groups at the NIH, Baylor College of Medicine, the University of Pennsylvania, and at Memorial Sloan Cancer Center (MSKCC) – have laid the foundation for this new therapeutic modality that is certain to gain importance in the treatment of ALL, CLL and B-cell lymphomas.

CD19 functions as a component of the B-cell co-receptor that enhances B-cell receptor signaling upon antigen encounter and CD19 expression is restricted to malignant and normal cells of the B-cell lineage [ 153 , 154 ]. In numerous preclinical studies, anti-CD19 CAR T-cells demonstrated selective lysis of B-lineage tumor lines and primary leukemia/lymphoma cells in vitro and also showed potent antitumor activity in murine xenograft and immunocompetent mouse models [ 152 , 155 – 164 ]. Subsequently in 2010, Kochenderfer et al. at the NIH reported the first successful use of anti-CD19 CAR T-cell treatment in a patient with advanced follicular lymphoma who received cyclophosphamide and fludarabine conditioning followed by a single infusion of autologous T-cells retrovirally transduced with a 2 nd generation CD19 CAR (CD28 costimulatory domain) along with IL-2 [ 165 ]. This patient experienced a dramatic partial response as well as B-cell aplasia in weeks 9 through 39 after CAR infusion, demonstrating the potency and CD19 specificity of this approach. In the expanded NIH cohort, which included 8 patients with lymphoma or CLL, 6 of 7 evaluable patients achieved objective disease responses, though in the context of concurrent cyclophosphamide/fludarabine chemotherapy [ 166 ]. Directly attributable to the CD19 CAR therapy, B-cell aplasia was observed in 4 of 8 patients for 6 months or more, demonstrating the persistence (and toxicity) of anti-CD19 CAR T-cells. Shortly thereafter, impressive responses for CLL patients were reported in a separate Phase I trial, where 3 patients were treated with a 2 nd generation anti-CD19 CAR that differed from the NIH construct in both the costimulatory domain (4-1BB in contrast to CD28) and the virus used for transduction (lentivirus as opposed to retrovirus) [ 80 , 134 ]. Despite all 3 patients having extensive and chemorefractory disease at the time of CAR infusion, all 3 experienced objective responses – 2 complete responses (CRs)– and the CAR T-cells expanded in vivo more than 1000-fold and persisted beyond 6 months. A recent update for 14 heavily pretreated and refractory CLL patients treated on this protocol described an overall major response rate of 57% - including 3 patients with durable CRs that have lasted up to 35 months and 5 patients with partial responses (PRs) [ 167 ].

Encouraging results have also been demonstrated in both pediatric and adult acute lymphoblastic leukemia, a more aggressive malignancy that is less immune-susceptible and responds poorly to DLI. This is partly due to low expression of costimulatory molecules by ALL cells [ 8 , 9 , 168 , 169 ]. One of the first CD19 CAR trials conducted in ALL patients was a Phase I study that used autologous T-cells retrovirally transduced to express an anti-CD19 CAR with a CD28 costimulatory protein. This trial enrolled 5 adult patients with relapsed disease [ 135 ]. Prior to CAR T-cell infusion, 2 patients had overt disease, 2 had MRD, and 1 was MRD negative. All patients underwent lymphodepletion with cyclophosphamide followed by a split-dose infusion of CAR-modified T-lymphocytes. All 4 patients with detectable disease had CRs and became MRD negative between days 8–59 after infusion, enabling eligible patients to receive allogeneic SCT. One patient with overt disease prior to CAR infusion relapsed with CD19+ disease 90 days after treatment, and all patients showed signs of normal CD19+ B-cell recovery, highlighting that CAR T-cells in these patients did not persist indefinitely in contrast to those in the aforementioned CLL trial that harbored the 4-1BB costimulatory domain. Importantly in this ALL trial, toxicity in the form of cytokine release syndrome was associated with a larger burden of disease at the time of CAR infusion, and the 2 patients with morphologic disease prior to treatment required high-dose steroid therapy for cytokine release syndrome, which likely abrogated the therapeutic effects of the CAR-modified lymphocytes. The initial promising results from this trial were recently updated to include responses for 16 adult patients with relapsed or refractory ALL who have been treated on this protocol [ 170 ]. The overall complete response rate to date is 88%. In those patients with gross morphologic disease prior to CAR infusion, 78% have experienced a CR, allowing many to receive alloSCT. In this trial, the benefit of treating the cytokine release syndrome with the IL-6 monoclonal antibody, tocilizumab, was demonstrated, and it was shown to relieve symptoms with a less profound impact on CAR T-cell expansion when compared to high-dose steroids.

Impressive response rates have similarly been observed in a separate ongoing Phase I trial for pediatric and adult relapsed ALL patients, which incorporates the identical CAR construct used in the above-referenced CLL trial (lentiviral transduction with 4-1BB costimulatory domain). Results were first reported for 2 pediatric patients who both demonstrated complete morphologic response to CAR therapy within 1 month despite recalcitrant disease, though 1 child relapsed 2 months later with CD19 negative lymphoblasts [ 79 ]. Both patients experienced significant toxicity, and the first child that was treated demonstrated severe but reversible cytokine release syndrome necessitating mechanical ventilation, vasopressor support, and aggressive medical therapy. Despite this, the tremendous expansion of anti-CD19 CAR T-cells to > 1000-fold in vivo and their persistence in 1 patient for >180 days is incredibly promising. Updates from this trial were also reported at a recent ASH meeting [ 145 ]. A total of 16 children and 4 adults with relapsed ALL have been treated and 82% of patients have experienced CRs - 3 patients are still pending evaluation. Unfortunately, 3 patients with an initial CR have since relapsed, reportedly with CD19+ disease. All patients in this trial experienced some degree of cytokine release syndrome and, as shown in previous trials, tocilizumab proved beneficial.

Importantly, 11 of the patients in this ALL trial had received prior allogeneic SCT [ 145 ]. For this cohort, the cells used to generate the anti-CD19 CAR treatment were collected from the recipient, however depending on the degree of chimerism at the time of pheresis, the majority of these cells were of donor origin. Encouragingly, GvHD was not observed in this group despite pre-treatment with cyclophosphamide, a phenomenon that could be attributable to the donor cells having acquired tolerance in the host as all patients were at least 6 months post-SCT [ 145 ]. In the alloSCT setting, investigators have already undertaken the next logical step, which is to determine whether allogeneic cells collected from healthy donors can be modified with an anti-CD19 CAR construct and used to treat leukemia patients. The advantage of this method is twofold: first, there is no leukemic contamination of the infused cells and, second, healthy donor lymphocytes are potentially more potent cytotoxic effectors since they have not been exposed to multiple rounds of chemotherapy and immunosuppressive agents. The primary concern with infusing large numbers of allogeneic cells is for GvHD, the most frequent complication of donor lymphocyte infusion (DLI), and thus investigators have proceeded cautiously with this approach [ 9 , 171 ]. In one study, 8 patients with relapsed ALL or CLL were treated with healthy donor allogeneic T-cells that were first enriched for virus-specific lymphocytes (cytomegalovirus (CMV), EBV, or adenovirus) prior to their transduction with a 2 nd generation anti-CD19 CAR containing the CD28 costimulatory domain [ 138 ]. This approach is advantageous because the specificity of the endogenous TCR is for viral antigens and thus infusion of bispecific T-cells, those with endogenous TCRs specific for viral antigens and ectopic TCRs specific for CD19, poses less risk for GvHD. Furthermore, viral reactivation is common in the post-SCT setting and could expand modified, CAR-expressing T-cells through viral TCR-signaling and potentially enhance their antitumor effect. In this pilot trial, the bispecific T-cells persisted for a median of 8 weeks and resulted in 2 objective responses -1 CR for 3 months and 1 PR for 2 months. No GvHD was observed. As predicted, EBV reactivation in 2 patients resulted in a concomitant increase of CD19 CAR transgene expression.

Lastly, a recent trial at a separate center investigated the safety of treating relapsed post-SCT patients with anti-CD19-CAR T-cells collected from their healthy donors; however, in this trial the modified donor T-cells were not enriched for any particular endogenous specificity [ 146 ]. Ten patients with either relapsed CLL or lymphoma who had undergone prior alloSCT and at least 1 DLI were enrolled and underwent a single infusion of allogeneic CAR T-cells without any preparative lymphodepletion. Surprisingly, no GvHD was observed though CAR cells were largely undetectable after 1 month. Three patients experienced regressions of their malignancy, with 1 ongoing CR in a CLL patient at 9 months. The next planned trial of this allogeneic CD19 CAR-modified therapy will incorporate preparative lymphodepletion, which would be predicted to both increase the antitumor potency and potentially heighten the risk for GvHD.

Currently, there are 20 open trials listed on the clinicaltrials.gov website as of June 2014 that are studying anti-CD19 CAR therapy in various permutations. For example, one study is using autologous anti-CD19 CAR cells for children with relapsed ALL that incorporate an EGFRt tracking/suicide construct and a methotrexate-resistance gene (clinicaltrials.gov identifier NCT01683279 ). Several CD19 CAR trials are recruiting at Baylor including a Phase 1 trial that will study the simultaneous infusion of both 2 nd and 3 rd generation CARs in patients with Non-Hodgkin Lymphoma (NHL) or CLL (clinicaltrials.gov identifier NCT01853631 ). CARs targeting the CD19 antigen are leading the way in the clinic and insights gained from these trials will be invaluable for the entire field.

Wilms tumor antigen 1

The Wilms tumor protein (WT-1) is a zinc-finger transcription factor that is important in normal cellular development and cell survival. In the human embryo, WT-1 is required for normal kidney development and, in adults, WT-1 has low expression levels in hematopoietic progenitor cells and in the ovary, testis, podocytes of the kidney, and peritoneal and pleural mesothelium [ 172 , 173 ]. Alternative splicing generates several isoforms of WT-1 and depending upon the cell in which the gene is expressed, it can function as either an oncogene or a tumor suppressor [ 174 ]. WT-1 represents a TAA as it is overexpressed in both leukemias (AML, CML, myelodysplastic syndrome [MDS], and ALL) and various solid tumors (ovary, breast, renal cell, colon, lung), where it acts as a putative oncogene [ 175 – 179 ]. Up to 70% of AML cases overexpress WT-1, where it is a marker of poor prognosis and minimal residual disease [ 180 – 183 ]. Although its precise biologic role in leukemia remains unknown, Yamagami et al. demonstrated that knockdown of WT-1 via antisense oligomers significantly inhibited the growth of primary leukemic clones, suggesting that the protein plays an important role in leukemogenesis [ 184 ]. Thus, WT-1 represents an attractive immunotherapeutic target, and there are currently 3 open clinical trials for adult leukemia patients that center around this unique antigen.

There are numerous preclinical studies that have demonstrated diverse and feasible approaches to target WT-1 in the clinic, and these have been expertly reviewed by O’Reilly et al. from MSKCC [ 185 ]. Briefly, several groups have demonstrated that WT-1-specific, functional CD4 and CD8 T-cells can be generated from healthy donor PBMC by stimulation with various WT-1 peptides [ 186 – 190 ]. Spontaneous autologous T-cell responses against WT-1 can also be detected in the peripheral blood of leukemia patients, providing rationale for either allogeneic or autologous ACT approaches [ 191 , 192 ]. More recently, Xue et al. have engineered a retroviral vector encoding the T-cell receptor alpha and beta chains derived from a WT-1 TCR specific for the HLA-A0201-restricted RMF peptide. This TCR construct was optimized by incorporating a disulfide bond to prevent alpha/beta mispairing and, when transduced into a CML patient’s T-cells, mediated prevention of autologous leukemia engraftment in an immunocompromised mouse model [ 100 , 193 ]. This TCR is now in clinical testing in London (see below). To broaden WT-1 specific ACT to patients with less common HLA subtypes, investigators have developed an elegant system in which donor T-cells are stimulated with pools of overlapping WT-1 peptides generating WT-1 specific T-cells with specificities that can be decoded using IFN-gamma secretion and a matrix of known peptide sequences. Using this approach T-cells specific for 27 different WT-1 peptides with diverse HLA-restriction were shown to lyse WT-1+ leukemic targets [ 194 ]. This approach, too, is now being tested in the clinic. As a final mention in the preclinical realm, Dao et al. have developed a full-length humanized TCR-mimic antibody from a phage display library that is specific for the WT-1 RMF peptide in the context of HLA-A0201. This antibody (ESK1) was shown to be highly avid and in 2 different mouse models, nearly ablated leukemia xenografts from 2 ALL cell lines, both alone and in concert with adoptive transfer of human effector cells [ 115 ]. The scFv from an affinity matured WT-1 TCR-mimic antibody has since been integrated into a CAR construct that has demonstrated lysis of solid tumor and B-cell leukemia cell lines [ 67 ].

As of June 2014, the clinicaltrials.gov website lists 3 Phase 1/2 trials that are using ACT to target the WT-1 antigen in leukemia patients. The first is based at University College in London and uses the retroviral vector developed by Xue et al. (discussed above) to redirect autologous T-cells from HLA-A0201-positive CML and AML patients via coexpression of a TCR specific for the A2-restricted WT-1 RMF peptide (clinicaltrials.gov identifier NCT01621724 ). This group hypothesizes that transducing and infusing fresh autologous, engineered T-cells will result in greater persistence of the WT-1 redirected cells compared to those from long-term culture. The second trial is sponsored by MSKCC and builds upon their success in generating functional, WT-1 specific T-cells from healthy donors with diverse HLA subtypes by in vitro stimulation with APCs pulsed with pools of overlapping WT-1 peptides [ 185 , 194 ]. This trial includes patients with AML, MDS, CML or ALL who are at high risk of relapse after alloSCT and utilizes infusions of WT-1-specific donor T-cells that are expanded in vitro , cryopreserved, and then infused at the time of recurrence or appearance of MRD. Reportedly, these infusions have been well tolerated without renal, hematopoietic, or GvHD toxicity, and they can transiently reduce or eliminate WT-1-expressing cells from the circulation [ 185 ] (clinicaltrials.gov identifier NCT00620633 ). The third trial is based at the Fred Hutchinson Cancer Research Center in Seattle and builds upon this center’s success in an earlier pilot trial. In the pilot trial, 11 HLA-A201-positive patients with AML or ALL who had received alloSCT were treated with adoptive transfer of donor-derived, in vitro expanded WT-1 RMF peptide-specific CD8+ T-cells. Here, the addition of the cytokine IL-21 to the ex vivo T-cell expansion protocol for the last 4 patients resulted in improved persistence of the WT-1-specific T-cells and expression of phenotypic markers associated with long-lived memory [ 25 ]. The infusions of large numbers of WT-1 specific T-cells (up to 1 × 10 10 cells/m 2 ) were safe and no GvHD, hematologic, or renal toxicity was observed. Encouragingly, of the 4 patients treated with antigen-specific T-cells generated in the presence of IL-21, all 4 experienced persistence of the WT-1 specific T-cells and demonstrated durable CRs (22–38 months post SCT) despite a ~90-95% risk of recurrence, though 1 patient has since relapsed. In the current Phase 1/2 trial, a TCR isolated from a very high avidity T-cell clone specific for the A2-restricted RMF WT-1 peptide has been isolated and is being retrovirally transduced into donor T-cells (similar to the London trial except in an allogeneic setting). In this trial, eligible patients are those with AML, CML, or MDS who are post-SCT, HLA-A0201-positive, and are at high-risk of relapse or who recur with overt or MRD positive disease. These patients will be treated with multiple infusions of donor EBV or CMV-specific T-cells that are transduced to coexpress the WT-1 specific TCR. The rationale for transducing only virus-specific T-cells is that in the allogeneic setting, transduction of T-cells with unknown secondary specificities would likely result in considerable GvHD. Patients will also receive IL-2 infusions to boost persistence of the antigen-specific cells.

Lewis Y

The Lewis Y antigen (Le Y ) is a difucosylated carbohydrate present on various cell surface proteins and lipids [ 195 ]. It is related to the Lewis blood group of antigens but is not expressed on red blood cells. In normal tissues, the Le Y antigen shows low levels of surface expression on the gastrointestinal mucosa, ciliated epithelium of the trachea and bronchus, and on neutrophils [ 196 , 197 ]. It is primarily studied as a potential tumor-associated antigen (TAA) in the context of solid malignancies since the Le Y antigen is highly expressed in 60-90% of epithelial cancers including those of the breast, pancreas, ovary, colon, stomach and lung [ 198 , 199 ]. A recent study also showed expression of the Lewis Y antigen in ~ 50% of AML and multiple myeloma (MM) cases, suggesting it could be a targetable TAA in a wide range of malignancies [ 200 ]. Its biologic function remains unknown though higher expression of Le Y correlates with poorer prognosis in lung cancer, suggesting a potential role for Lewis Y in maintaining a malignant phenotype [ 201 ].

Preclinical validation of the Le Y antigen gained momentum when Kitamura et al. developed an anti-Le Y humanized monoclonal antibody – known as Hu3S193 [ 202 ]. This antibody was used alone and as an immunoconjugate in several early phase clinical trials targeting the Lewis Y antigen in patients, first in those with solid malignancies. The humanized monoclonal antibody Hu3S193 (also used to generate the anti-Le Y CAR discussed below) was tested in a Phase I trial in 15 patients with primarily breast, colorectal, or lung cancer. There were no objective tumor responses, however, there was significant uptake of the antibody in tumor metastases and no uptake in normal tissue. Critically, the antibody infusion was safe with only one Grade 3 or 4 adverse effect - an elevated alkaline phosphatase in a patient with extensive hepatic metastases [ 203 ]. In an effort to increase the potency of tumor response, two Phase I trials were conducted using the Lewis Y antibody, Hu3S193, conjugated to either doxorubicin or calicheamicin. In the Hu3S193-doxorubicin immunoconjugate trial, 66 patients with mainly metastatic colon or breast cancer were treated, and significant, dose-limiting GI toxicity was observed, likely due to Lewis Y expression on normal GI epithelium. Objective responses were seen in only 2 patients [ 204 ]. In the Hu3S193-calicheamicin immunoconjugate trial, 9 patients with solid tumors were enrolled. Disappointingly, this conjugate showed primary localization to the liver instead of tumor and demonstrated rapid hepatic clearance from the circulation [ 205 ].

The promising yet limited effects of the Hu3S193 antibody laid the foundation for the targeting of Le Y using ACT. In preclinical studies, Hu3S193 was used to generate a 2 nd generation anti-Le Y CAR, which was first tested against various malignant epithelial-derived cell lines and in a mouse xenograft model of ovarian cancer. The anti-Le Y CAR T-cells lysed breast and colorectal cell lines in vitro , and lysis correlated positively with the level of Le Y expression. Importantly, no IFN-γ release or lysis was observed against neutrophils, which have been shown to express Lewis Y at low levels. Further, in immunocompromised mice anti- Le Y CAR T-cells mediated regression of established human ovarian tumors, though tumors did eventually recur [ 198 ]. More recently, this same CAR was used in preclinical testing against AML and MM, which also show overexpression of the Lewis Y antigen. The CAR T-cells lysed human MM and AML cell lines in vitro and delayed the incidence of plasmacytomas in a NOD/SCID mouse model, though no lysis of primary malignant cells or rejection of established myeloma or AML was demonstrated [ 200 ].

The first and (thus far) only ACT clinical trial targeting the Le Y antigen in patients utilized the 2 nd generation anti-Le Y CAR mentioned above, which demonstrated activity against both solid and hematologic tumors in preclinical studies. Results from the first 5 enrolled patients, all with AML, were recently published and are summarized here [ 43 ]. This Phase I trial enrolled patients with high-risk or relapsed/refractory AML or MM whose tumors demonstrated expression of Le Y on at least 20% of blasts, with a median fluorescence intensity twice that of normal lymphocytes. It is worth noting that the first 5 patients enrolled had relatively low Lewis Y expression compared to the patient samples used in the study that first described the presence of Lewis Y antigen in AML and MM [ 200 ]. Three of the four patients who underwent CAR T-cell infusion (one patient died from induction chemotherapy) had cytogenetic MRD prior to CAR T-cell infusion; the fourth patient had 70% blasts in the bone marrow as well as circulating disease. Patients were preconditioned with fludarabine and cytarabine and then infused with a median of 4.45 × 10 6 anti-Le Y CAR T-cells/kg. As a comparison, these cell doses are comparable to those administered in the successful CD19 CAR clinical trials [ 134 ]. There were no grade 3 or 4 toxicities, and there was evidence of biologic activity though responses were modest at best. Of the 3 patients with MRD prior to CAR T-cell infusion, 1 demonstrated a sustained morphologic remission of 23 months though cytogenetic clones remained detectable, the 2 nd patient showed a transient cytogenetic remission of 5 months, and the 3 rd patient did not respond and relapsed 49 days after infusion. The 4 th patient who had significant disease prior to anti-Le Y CAR treatment had a very transient reduction in blasts, though the effect attributable to the CAR cells in the context of pretreatment with fludarabine and cytarabine is difficult to discern. Encouragingly, the CAR T-cells did show trafficking to the bone marrow and persisted in 3 of the 4 patients for 2, 4 and 10 months, though with variable transgene copy number by qualitative PCR. Perhaps most disappointingly, the 3 patients who showed some biologic response all relapsed with myeloblasts that still expressed the Lewis Y antigen with comparable MFIs to their pre-CAR treatment disease; there was no antigenic shift despite persistence of the CAR cells. The authors hypothesize that this could be due to an immunosuppressive microenvironment or downregulation in transgene expression. It might simply be related to the relatively low expression of Lewis Y on the myeloblasts and inadequate activation of the modified cells. The authors suggest the next anti-Le Y CAR T-cell trial will be performed in lung cancer patients, where there is a more dense and uniform expression of the Le Y antigen.

κ Light chain

The major long-term toxicity associated with the successful anti-CD19 CAR T-cell trials discussed above has been B-cell aplasia, which is secondary to the expression of CD19 on normal and B-cell precursors [ 79 , 80 , 134 , 135 , 164 ]. A strategy to avoid this adverse effect has been developed using engineered 2 nd generation CAR T-cells with specificity for the κ light chain of surface immunoglobulin (sIg) within the B-cell receptor [ 206 ]. The concept behind this approach is that B-cell malignancies are clonal disorders wherein a patient’s malignant cells express a κ or λ-restricted sIg, but not both. In those patients with a κ-restricted malignancy, the anti-κ CAR T-cells would ideally eliminate all malignant cells and, consequently, normal B-cells with κ expression; however, normal λ-restricted B cells would be left untouched providing these patients with adequate B-cell immunity [ 207 , 208 ].

In preclinical studies, the κ-light chain specific CAR T-cells selectively lysed κ-expressing lymphoma and leukemic cell lines as well as autologous and allogeneic κ-restricted primary CLL cells [ 206 ]. In vivo , human T-cells retrovirally transduced with the anti-κ CAR mediated regression of lymphoma xenografts. As an aside, this was among the first reports to show the importance of a CD28 costimulatory domain in the CAR construct, and it confirmed in this preclinical study that CD28 improved the expansion of the engineered anti-κ T-cells [ 206 , 209 ]. A Phase I trial is currently recruiting patients with relapsed CLL, NHL, or MM to study treatment with autologous 2 nd -generation anti-κ CAR T-cells (clinicaltrials.gov identifier NCT00881920 ). The trial will assess the safety and, as a secondary measure, the survival and function of anti-κ T-cells at 3 escalating T-cell doses after lymphodepletion with cyclophosphamide. It will be important to see whether antigen escape limits the success of this approach since MM and CLL are known to have variable expression of sIg [ 210 – 212 ]. Moreover, the antibody portion of the CAR construct is derived from a mouse, and the immunogenicity of this CAR in humans remains to be seen. Conversely and in support of this approach, targeting the B-cell receptor in lymphoma through idiotype vaccines has shown great promise and points to the feasibility of using the B-cell receptor (whether the idiotype or the light chain portion) as a TAA [ 41 ].

HA-1 and other minor histocompatibility antigens

As defined above, minor histocompatibility antigens (mHAs) are peptides derived from endogenous, polymorphic proteins that differ between donor and recipient and are thought to account for much of the GvL effect within HLA-matched donor-recipient pairs [ 213 ]. These antigens can also trigger GvHD, and therefore the major goal with mHAs has been to identify and target mHAs that show predominant expression in the hematopoietic compartment. Strong preclinical evidence for targeting these mHAs was demonstrated in an immunocompetent mouse model where targeting a single mHA (B6 dom1 ) resulted in complete eradication of leukemia without GvHD [ 214 ]. Two recent clinical trials have investigated unique approaches towards this common objective of treating leukemia by targeting hematopoietic-restricted mHAs.

In one clinical trial utilizing adoptive transfer of mHA-specific T-cells, investigators first designed an in vitro culture system to enrich for mHA-specific donor T-cells [ 215 ]. In this trial, PBMC were collected from patients at post-transplant timepoints when their hematopoietic system had been replaced by donor cells. These donor-derived cells were then stimulated in vitro with pre-transplant, irradiated recipient PBMC and recipient EBV-LCLs (Epstein Barr Virus-transformed B lymphoblastoid cell lines) in an effort to generate donor T-cells specific for hematopoietic mHAs [ 216 ]. CD8+ T-cell clones were then generated using limiting dilution cloning. Donor CD8+ clones that lysed recipient EBV-LCLs but neither donor EBV-LCLs nor recipient fibroblasts were selected for treatment of 7 patients with relapsed MDS or ALL after alloSCT. Patients received cytoreductive chemotherapy but not specific lymphodepletion prior to T-cell infusions, which were administered in a dose-escalation protocol. Unfortunately, most of the patients had GvHD prior to treatment so it was difficult to grade the degree of GvHD caused by these T-cells, though no cases were directly attributable to the clones. Surprisingly, the major toxicity observed was pulmonary toxicity, which occurred in 3 patients and underscores the reality that adoptively transferred T-cells tend to initially accumulate in the lungs making this a vulnerable site for adverse effects [ 217 ]. Five of 7 patients achieved transient CRs, and 3 of these responses were directly attributable to the CTL clones and not the cytoreductive chemotherapy. A genome-wide, single nucleotide polymorphism-based correlation was used to identify the mHA targeted by 3 of the generated clones - 2 that were novel [ 218 ]. Interestingly, mRNA expression analysis suggested that leukemic blasts downregulated expression of 1 of the targeted mHAs after CTL treatment, again illustrating that it may be important to target proteins directly involved in leukemogenesis. Two of the patients who demonstrated significant pulmonary toxicity were infused with clones that recognized epitopes from proteins also expressed on the pulmonary alveolar epithelium, and the CTLs were shown to be directly causative in these adverse reactions. The CTLs showed potent effector function but did not persist past 21 days, possibly as a result of their extended time in culture that resulted in a differentiated, effector population of CD8+ T-cells. Unfortunately, all patients who demonstrated an initial response relapsed and succumbed to their disease.

In a more recent Phase I study, Meij et al. tested the feasibility and safety of treating relapsed post-SCT AML and CML patients with donor-derived T-cells specific for the mHA, HA-1 [ 35 , 219 ]. HA-1-specific T-cells were generated from healthy donor PBMC using donor dendritic cells pulsed with the HLA-A2 restricted HA-1 peptide during a 5-week in vitro culture period. The cells were then infused into patients in the absence of preconditioning or in vivo cytokine administration. The cells were primarily from the effector memory subset and 6-27% were tetramer positive (i.e. HA-1-specific). Unfortunately, no objective responses were demonstrated though a patient with CML did have stable disease for 3 months. HA-1 specific T-cells were detected only in this CML patient and were present for ~ 8 weeks. No GvHD was reported. The authors concluded that more potent responses might be generated by shortening the in vitro culture process possibly via ectopic TCR alpha/beta transfer and also through use of physiologic concentrations of cytokines during the in vitro expansion. Towards this goal, a codon optimized and cysteine modified HA-1-TCR α/β retroviral construct has been designed for use in clinical trials [ 108 ].

BCR-ABL

Tumor-specific antigens (neoantigens) within the BCR-ABL1 fusion tyrosine kinase have also been investigated as targets for ACT of CML. Several groups have shown that CML patients have functional, circulating T-cells specific for these neoantigens that can be expanded with a peptide vaccine [ 39 , 53 , 220 ]. A recent clinical trial investigated the feasibility and safety of prophylactically administering donor CD8+ T-cells enriched for specificities against peptides from WT-1, PR1, and BCR-ABL to CML patients after T-cell depleted alloSCT [ 57 ]. Five patients were treated with cells enriched for CTL with specificity for HLA-A3, A11, or B8-restricted BCR-ABL neopeptides. In these patients, the cells infused were largely polyclonal DLIs with wide ranges in the percentage of BCR-ABL-specific cells actually administered – from 0.1 – 17%. Though few patients were enrolled and the effects of therapy attributable to ACT are indiscernible from those related to alloSCT, 1 patient who received large numbers of BCR-ABL specific donor T-cells that exhibited robust in vitro cytotoxicity has remained in molecular remission for > 40 months and antigen-specific cells have persisted at high frequencies for >1 year.

A separate report described the successful treatment of a CML patient with leukemia-reactive CTL in 1999, prior to the advent of many of the engineering techniques now available. In this study, the CML patient had relapsed with accelerated-phase disease after alloSCT and DLI and was treated with donor cells enriched for leukemia-specific antigens via multiple rounds of in vitro stimulation with patient leukemia cells. The T-cells were not fully characterized but potentially recognized neoepitopes from BCR-ABL among others. This patient experienced molecular remission for 2 years until she later died of ischemic heart disease [ 221 ]. These studies offer proof-of-principle for targeting leukemia neoantigens though larger scale studies are needed using modified T-cells or updated in vitro expansion protocols. Table 2 summarizes the antigens discussed in the section. Table 2 Summary of hematologic tumor antigens being targeted in clinical trials of ACT Antigen HLA-restriction Hematologic Malignancy † Immunotherapeutic Potential CD19 No ALL, CLL, Lymphoma 1) Common to several lymphoid malignancies 2) Highly potent effectors have been developed 3) Cell surface protein that does not require processing or MHC presentation 4) Anti-leukemia effects must be balanced with toxicity against normal B cells WT-1 Yes AML, CML, MDS, ALL 1) Has been studied primarily in myeloid hematologic malignancies, although recent work suggests its potential in lymphoid malignancies [ 222 ] 2) Minimal expression in normal tissues 3) Requires intracellular processing and antigen presentation Lewis Y No AML, MM 1) At this time, studies are limited to AML and MM 2) Studies to date have shown moderate potency against malignant cells 3) May be limited by GI toxicity κ Light Chain No CLL, lymphoma, MM 1) Limited to lymphoid malignancies and MM 2) Still in early stages of development, therefore potency is difficult to assess mHA Yes Applicable to all hematologic malignancies 1) Potent immune responses against malignant cells, including stem cells 2) May also trigger GvHD 3) Limited by the frequency of the minor allele in the population 4) Difficult to predict off-target tissue expression BCR-ABL Yes CML 1) Limited studies using ACT to target BCR-ABL in the era of tyrosine kinase inhibitors 2) Mainly useful in CML and possibly Ph + ALL † Expression of the antigens has been reported in other hematologic and solid tumor malignancies.

Conclusions

In summary, ACT represents a promising strategy for treating leukemia patients. The list of antigens discussed above is by no means exhaustive and many ACT strategies are in the pipeline to target other leukemia antigens including PR1 [ 29 ], human telomerase reverse transcriptase (hTERT) [ 26 ], receptor tyrosine kinase-like orphan receptor 1 (ROR1) [ 45 ], CD23 [ 223 ], CD123 [ 224 ], preferentially expressed antigen in melanoma (PRAME) [ 27 ], hyaluronan-mediated motility receptor (HMMR/Rhamm) [ 28 ], CD22 [ 44 ], cathepsin G [ 30 ] and aurora kinase a (AURKA) [ 225 ] among others. The clinical success achieved using anti-CD19 CARs has shifted momentum in favor of this type of engineered receptor, but exciting clinical trials utilizing ectopic TCR α/β receptors and even conventional T-cells are also underway. Significant challenges remain in outlining the best setting for ACT of leukemia, though this will likely vary by disease type, targeted antigen, and T-cell approach. Moreover, incorporating automation and standardization will be critical to shifting the ACT field away from intricate protocols and small, single-center trials towards broader applicability. The goal is to harness and refine the tremendous specificity and potency of lymphocytes, best evidenced by the ability of alloSCT and DLI to cure otherwise incurable diseases (CML, CLL), into a T-cell treatment for leukemia that is more effective and less toxic than current standard of care therapies.

Abbreviations

Acute lymphoblastic leukemia

Acute myeloid leukemia

Adoptive cellular therapy

Allogeneic stem cell transplantation

Antigen presenting cells

Chimeric antigen receptor

Chronic lymphocytic leukemia

Chronic myeloid leukemia

Complete response

Cytomegalovirus

Cytotoxic T-lymphocytes

Donor lymphocyte infusion

Epstein Barr Virus

Graft-versus-host disease

Graft-versus-leukemia

Human leukocyte antigen

Major histocompatibility complex

Minimal residual disease

Minor histocompatibility antigen

Multiple myeloma

Myelodysplastic syndrome

Natural killer cell

Non-Hodgkin Lymphoma

Partial response

Peripheral blood mononuclear cells

Post-allogeneic stem cell transplant lymphoproliferative disease

Single chain variable fragment

Surface immunoglobulin

T-cell receptor

Tumor-associated antigen

Tumor infiltrating lymphocyte

Wilms tumor antigen.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

HG wrote the manuscript with assistance from AM. EM and GA outlined and revised the manuscript. All authors read and approved the final manuscript.

References

1. Apperley JF Jones L Hale G Waldmann H Hows J Rombos Y Tsatalas C Marcus RE Goolden AW Gordon-Smith EC Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse Bone Marrow Transplant 1986 1 53 66 3332120

2. Horowitz MM Gale RP Sondel PM Goldman JM Kersey J Kolb HJ Rimm AA Ringden O Rozman C Speck B Graft-versus-leukemia reactions after bone marrow transplantation Blood 1990 75 555 562 2297567

3. Wagner JE Thompson JS Carter SL Kernan NA Unrelated Donor Marrow Transplantation T Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial Lancet 2005 366 733 741 16125590 10.1016/S0140-6736(05)66996-6

4. Korngold R Leighton C Manser T Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation Transplantation 1994 58 278 287 7914387

5. Marmont AM Horowitz MM Gale RP Sobocinski K Ash RC van Bekkum DW Champlin RE Dicke KA Goldman JM Good RA T-cell depletion of HLA-identical transplants in leukemia Blood 1991 78 2120 2130 1912589

6. Pollard CM Powles RL Millar JL Shepherd V Milan S Lakhani A Zuiable A Treleaven J Helenglass G Leukaemic relapse following Campath 1 treated bone marrow transplantation for leukaemia Lancet 1986 2 1343 1344 2878219 10.1016/s0140-6736(86)91482-0

7. Collins RH Jr Goldstein S Giralt S Levine J Porter D Drobyski W Barrett J Johnson M Kirk A Horowitz M Parker P Donor leukocyte infusions in acute lymphocytic leukemia Bone Marrow Transplant 2000 26 511 516 11019840 10.1038/sj.bmt.1702555

8. Collins RH Jr Shpilberg O Drobyski WR Porter DL Giralt S Champlin R Goodman SA Wolff SN Hu W Verfaillie C List A Dalton W Ognoskie N Chetrit A Antin JH Nemunaitis J Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation J Clin Oncol 1997 15 433 444 9053463 10.1200/JCO.1997.15.2.433

9. Kolb HJ Schattenberg A Goldman JM Hertenstein B Jacobsen N Arcese W Ljungman P Ferrant A Verdonck L Niederwieser D van Rhee F Mittermueller J de Witte T Holler E Ansari H European Group for B, Marrow Transplantation Working Party Chronic L Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients Blood 1995 86 2041 2050 7655033

10. Khouri IF Lee MS Saliba RM Andersson B Anderlini P Couriel D Hosing C Giralt S Korbling M McMannis J Keating MJ Champlin RE Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival Exp Hematol 2004 32 28 35 14725898 10.1016/j.exphem.2003.09.021

11. Levine JE Braun T Penza SL Beatty P Cornetta K Martino R Drobyski WR Barrett AJ Porter DL Giralt S Leis J Holmes HE Johnson M Horowitz M Collins RH Jr Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation J Clin Oncol 2002 20 405 412 11786567 10.1200/JCO.2002.20.2.405

12. Kolb HJ Graft-versus-leukemia effects of transplantation and donor lymphocytes Blood 2008 112 4371 4383 19029455 10.1182/blood-2008-03-077974

13. Bleakley M Riddell SR Molecules and mechanisms of the graft-versus-leukaemia effect Nat Rev Cancer 2004 4 371 380 15122208 10.1038/nrc1365

14. Alatrash G Molldrem JJ Vaccines as consolidation therapy for myeloid leukemia Expert Rev Hematol 2011 4 37 50 21322777 10.1586/ehm.10.80 PMC3098525

15. Rosenberg SA Raising the bar: the curative potential of human cancer immunotherapy Sci Transl Med 2012 4 127ps128 10.1126/scitranslmed.3003634 PMC6292198 22461638

16. Tran E Turcotte S Gros A Robbins PF Lu YC Dudley ME Wunderlich JR Somerville RP Hogan K Hinrichs CS Parkhurst MR Yang JC Rosenberg SA Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer Science 2014 344 641 645 24812403 10.1126/science.1251102 PMC6686185

17. Schietinger A Greenberg PD Tolerance and exhaustion: defining mechanisms of T cell dysfunction Trends Immunol 2014 35 51 60 24210163 10.1016/j.it.2013.10.001 PMC3946600

18. Cheever MA Allison JP Ferris AS Finn OJ Hastings BM Hecht TT Mellman I Prindiville SA Viner JL Weiner LM Matrisian LM The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research Clin Cancer Res 2009 15 5323 5337 19723653 10.1158/1078-0432.CCR-09-0737 PMC5779623

19. Inoue K Ogawa H Sonoda Y Kimura T Sakabe H Oka Y Miyake S Tamaki H Oji Y Yamagami T Tatekawa T Soma T Kishimoto T Sugiyama H Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia Blood 1997 89 1405 1412 9028964

20. Pham CT Neutrophil serine proteases: specific regulators of inflammation Nat Rev Immunol 2006 6 541 550 16799473 10.1038/nri1841

21. Molldrem J Dermime S Parker K Jiang YZ Mavroudis D Hensel N Fukushima P Barrett AJ Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells Blood 1996 88 2450 2457 8839835

22. Molldrem JJ Lee PP Wang C Felio K Kantarjian HM Champlin RE Davis MM Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia Nat Med 2000 6 1018 1023 10973322 10.1038/79526

23. Hofmann O Caballero OL Stevenson BJ Chen YT Cohen T Chua R Maher CA Panji S Schaefer U Kruger A Lehvaslaiho M Carninci P Hayashizaki Y Jongeneel CV Simpson AJ Old LJ Hide W Genome-wide analysis of cancer/testis gene expression Proc Natl Acad Sci U S A 2008 105 20422 20427 19088187 10.1073/pnas.0810777105 PMC2603434

24. Parkhurst MR Yang JC Langan RC Dudley ME Nathan DA Feldman SA Davis JL Morgan RA Merino MJ Sherry RM Hughes MS Kammula US Phan GQ Lim RM Wank SA Restifo NP Robbins PF Laurencot CM Rosenberg SA T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis Mol Ther 2011 19 620 626 21157437 10.1038/mt.2010.272 PMC3048186

25. Chapuis AG Ragnarsson GB Nguyen HN Chaney CN Pufnock JS Schmitt TM Duerkopp N Roberts IM Pogosov GL Ho WY Ochsenreither S Wolfl M Bar M Radich JP Yee C Greenberg PD Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients Sci Transl Med 2013 5 174ra127 10.1126/scitranslmed.3004916 PMC3678970 23447018

26. Miyazaki Y Fujiwara H Asai H Ochi F Ochi T Azuma T Ishida T Okamoto S Mineno J Kuzushima K Shiku H Yasukawa M Development of a novel redirected T-cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia Blood 2013 121 4894 4901 23641014 10.1182/blood-2012-11-465971

27. Amir AL van der Steen DM van Loenen MM Hagedoorn RS de Boer R Kester MD de Ru AH Lugthart GJ van Kooten C Hiemstra PS Jedema I Griffioen M van Veelen PA Falkenburg JH Heemskerk MH PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer Clin Cancer Res 2011 17 5615 5625 21771875 10.1158/1078-0432.CCR-11-1066

28. Spranger S Jeremias I Wilde S Leisegang M Starck L Mosetter B Uckert W Heemskerk MH Schendel DJ Frankenberger B TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo Blood 2012 119 3440 3449 22371883 10.1182/blood-2011-06-357939

29. Ma Q Wang C Jones D Quintanilla KE Li D Wang Y Wieder ED Clise-Dwyer K Alatrash G Mj Y Munsell MF Lu S Qazilbash MH Molldrem JJ Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model Cytotherapy 2010 12 1056 1062 20735170 10.3109/14653249.2010.506506 PMC3365857

30. Zhang M Sukhumalchandra P Enyenihi AA St John LS Hunsucker SA Mittendorf EA Sergeeva A Ruisaard K Al-Atrache Z Ropp PA Jakher H Rodriguez-Cruz T Lizee G Clise-Dwyer K Lu S Molldrem JJ Glish GL Armistead PM Alatrash G A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia Clin Cancer Res 2013 19 247 257 23147993 10.1158/1078-0432.CCR-12-2753 PMC3537920

31. Pizzitola I Anjos-Afonso F Rouault-Pierre K Lassailly F Tettamanti S Spinelli O Biondi A Biagi E Bonnet D Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo Leukemia 2014 10.1038/leu.2014.62 24504024

32. Ochsenreither S Majeti R Schmitt T Stirewalt D Keilholz U Loeb KR Wood B Choi YE Bleakley M Warren EH Hudecek M Akatsuka Y Weissman IL Greenberg PD Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen Blood 2012 119 5492 5501 22529286 10.1182/blood-2011-07-365890 PMC3369684

33. Klippel ZK Chou J Towlerton AM Voong LN Robbins P Bensinger WI Warren EH Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC Gene Ther 2014 21 337 342 24451117 10.1038/gt.2013.87 PMC4040020

34. Goodyear O Agathanggelou A Novitzky-Basso I Siddique S McSkeane T Ryan G Vyas P Cavenagh J Stankovic T Moss P Craddock C Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia Blood 2010 116 1908 1918 20530795 10.1182/blood-2009-11-249474

35. Meij P Jedema I van der Hoorn MA Bongaerts R Cox L Wafelman AR Marijt EW Willemze R Falkenburg JH Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot study Haematologica 2012 97 1205 1208 22511490 10.3324/haematol.2011.053371 PMC3409818

36. Akatsuka Y Nishida T Kondo E Miyazaki M Taji H Iida H Tsujimura K Yazaki M Naoe T Morishima Y Kodera Y Kuzushima K Takahashi T Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens J Exp Med 2003 197 1489 1500 12771180 10.1084/jem.20021925 PMC2193899

37. Armistead PM Liang S Li H Lu S Van Bergen CA Alatrash G St John L Hunsucker SA Sarantopoulos S Falkenburg JH Molldrem JJ Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data PloS one 2011 6 e23217 21858034 10.1371/journal.pone.0023217 PMC3153501

38. Stumpf AN van der Meijden ED van Bergen CA Willemze R Falkenburg JH Griffioen M Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity Blood 2009 114 3684 3692 19706888 10.1182/blood-2009-03-208017

39. Rezvani K Grube M Brenchley JM Sconocchia G Fujiwara H Price DA Gostick E Yamada K Melenhorst J Childs R Hensel N Douek DC Barrett AJ Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation Blood 2003 102 2892 2900 12829610 10.1182/blood-2003-01-0150

40. Graf C Heidel F Tenzer S Radsak MP Solem FK Britten CM Huber C Fischer T Wolfel T A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells Blood 2007 109 2985 2988 17119119 10.1182/blood-2006-07-032839

41. Schuster SJ Neelapu SS Gause BL Janik JE Muggia FM Gockerman JP Winter JN Flowers CR Nikcevich DA Sotomayor EM McGaughey DS Jaffe ES Chong EA Reynolds CW Berry DA Santos CF Popa MA McCord AM Kwak LW Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma J Clin Oncol 2011 29 2787 2794 21632504 10.1200/JCO.2010.33.3005 PMC3139394

42. Tamai Y Hasegawa A Takamori A Sasada A Tanosaki R Choi I Utsunomiya A Maeda Y Yamano Y Eto T Koh KR Nakamae H Suehiro Y Kato K Takemoto S Okamura J Uike N Kannagi M Potential contribution of a novel Tax epitope-specific CD4+ T cells to graft-versus-Tax effect in adult T cell leukemia patients after allogeneic hematopoietic stem cell transplantation J Immunol 2013 190 4382 4392 23475215 10.4049/jimmunol.1202971

43. Ritchie DS Neeson PJ Khot A Peinert S Tai T Tainton K Chen K Shin M Wall DM Honemann D Gambell P Westerman DA Haurat J Westwood JA Scott AM Kravets L Dickinson M Trapani JA Smyth MJ Darcy PK Kershaw MH Prince HM Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia Mol Ther 2013 21 2122 2129 23831595 10.1038/mt.2013.154 PMC3831035

44. Fry TJ Mackall CL T-cell adoptive immunotherapy for acute lymphoblastic leukemia Hematology Am Soc Hematol Educ Program 2013 2013 348 353 24319203 10.1182/asheducation-2013.1.348 PMC7569491

45. Hudecek M Lupo-Stanghellini MT Kosasih PL Sommermeyer D Jensen MC Rader C Riddell SR Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells Clin Cancer Res 2013 19 3153 3164 23620405 10.1158/1078-0432.CCR-13-0330 PMC3804130

46. Bleakley M Turtle CJ Riddell SR Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation Expert Rev Hematol 2012 5 409 425 22992235 10.1586/ehm.12.28 PMC3590108

47. Robbins PF Lu YC El-Gamil M Li YF Gross C Gartner J Lin JC Teer JK Cliften P Tycksen E Samuels Y Rosenberg SA Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells Nat Med 2013 19 747 752 23644516 10.1038/nm.3161 PMC3757932

48. Lu YC Yao X Li YF El-Gamil M Dudley ME Yang JC Almeida JR Douek DC Samuels Y Rosenberg SA Robbins PF Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression J Immunol 2013 190 6034 6042 23690473 10.4049/jimmunol.1202830 PMC3679246

49. van Rooij N van Buuren MM Philips D Velds A Toebes M Heemskerk B van Dijk LJ Behjati S Hilkmann H El Atmioui D Nieuwland M Stratton MR Kerkhoven RM Kesmir C Haanen JB Kvistborg P Schumacher TN Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma J Clin Oncol 2013 31 e439 442 24043743 10.1200/JCO.2012.47.7521 PMC3836220

50. Mardis ER Ding L Dooling DJ Larson DE McLellan MD Chen K Koboldt DC Fulton RS Delehaunty KD McGrath SD Fulton LA Locke DP Magrini VJ Abbott RM Vickery TL Reed JS Robinson JS Wylie T Smith SM Carmichael L Eldred JM Harris CC Walker J Peck JB Du F Dukes AF Sanderson GE Brummett AM Clark E McMichael JF Recurring mutations found by sequencing an acute myeloid leukemia genome N Engl J Med 2009 361 1058 1066 19657110 10.1056/NEJMoa0903840 PMC3201812

51. Wang L Lawrence MS Wan Y Stojanov P Sougnez C Stevenson K Werner L Sivachenko A DeLuca DS Zhang L Zhang W Vartanov AR Fernandes SM Goldstein NR Folco EG Cibulskis K Tesar B Sievers QL Shefler E Gabriel S Hacohen N Reed R Meyerson M Golub TR Lander ES Neuberg D Brown JR Getz G Wu CJ SF3B1 and other novel cancer genes in chronic lymphocytic leukemia N Engl J Med 2011 365 2497 2506 22150006 10.1056/NEJMoa1109016 PMC3685413

52. Bocchia M Wentworth PA Southwood S Sidney J McGraw K Scheinberg DA Sette A Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules Blood 1995 85 2680 2684 7742526

53. Butt NM Rojas JM Wang L Christmas SE Abu-Eisha HM Clark RE Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects Haematologica 2005 90 1315 1323 16219567

54. Clark RE Dodi IA Hill SC Lill JR Aubert G Macintyre AR Rojas J Bourdon A Bonner PL Wang L Christmas SE Travers PJ Creaser CS Rees RC Madrigal JA Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein Blood 2001 98 2887 2893 11698267 10.1182/blood.v98.10.2887

55. Yotnda P Firat H Garcia-Pons F Garcia Z Gourru G Vernant JP Lemonnier FA Leblond V Langlade-Demoyen P Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia J Clin Invest 1998 101 2290 2296 9593785 10.1172/JCI488 PMC508817

56. Bornhauser M Thiede C Babatz J Schetelig J Illmer T Kiani A Platzbecker U Herr W Rieber EP Ehninger G Schmitz M Infusion of bcr/abl peptide-reactive donor T cells to achieve molecular remission of chronic myeloid leukemia after CD34+ selected allogeneic hematopoietic cell transplantation Leukemia 2006 20 2055 2057 16990776 10.1038/sj.leu.2404383

57. Bornhauser M Thiede C Platzbecker U Kiani A Oelschlaegel U Babatz J Lehmann D Holig K Radke J Tuve S Wermke M Wehner R Jahnisch H Bachmann MP Rieber EP Schetelig J Ehninger G Schmitz M Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia Blood 2011 117 7174 7184 21540460 10.1182/blood-2010-09-308569

58. Stevenson GT Stevenson FK Antibody to a molecularly-defined antigen confined to a tumour cell surface Nature 1975 254 714 716 47617 10.1038/254714a0

59. de Vos van Steenwijk PJ Heusinkveld M Ramwadhdoebe TH Lowik MJ van der Hulst JM Goedemans R Piersma SJ Kenter GG van der Burg SH An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer Cancer Res 2010 70 2707 2717 20233872 10.1158/0008-5472.CAN-09-4299

60. Heslop HE Slobod KS Pule MA Hale GA Rousseau A Smith CA Bollard CM Liu H Wu MF Rochester RJ Amrolia PJ Hurwitz JL Brenner MK Rooney CM Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients Blood 2010 115 925 935 19880495 10.1182/blood-2009-08-239186 PMC2817637

61. Bollard CM Gottschalk S Leen AM Weiss H Straathof KC Carrum G Khalil M Wu MF Huls MH Chang CC Gresik MV Gee AP Brenner MK Rooney CM Heslop HE Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer Blood 2007 110 2838 2845 17609424 10.1182/blood-2007-05-091280 PMC2018666

62. Kurihara K Shimizu Y Takamori A Harashima N Noji M Masuda T Utsunomiya A Okamura J Kannagi M Human T-cell leukemia virus type-I (HTLV-I)-specific T-cell responses detected using three-divided glutathione-S-transferase (GST)-Tax fusion proteins J Immunol Methods 2006 313 61 73 16723135 10.1016/j.jim.2006.03.013

63. Aleksic M Liddy N Molloy PE Pumphrey N Vuidepot A Chang KM Jakobsen BK Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies Eur J Immunol 2012 42 3174 3179 22949370 10.1002/eji.201242606 PMC3776049

64. Schreiber RD Old LJ Smyth MJ Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion Science 2011 331 1565 1570 21436444 10.1126/science.1203486

65. Gross G Waks T Eshhar Z Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity Proc Natl Acad Sci U S A 1989 86 10024 10028 2513569 10.1073/pnas.86.24.10024 PMC298636

66. Kershaw MH Westwood JA Darcy PK Gene-engineered T cells for cancer therapy Nat Rev Cancer 2013 13 525 541 23880905 10.1038/nrc3565

67. Kuo T Hasan A Zhao Q Selvakumar A T Cells Expressing Cars Directed Against HLA-0201-Rmf WT-1 Peptide Complex Can Effectively Eradicate WT1+ A0201+ Tumor Cells In-Vitro Biol Blood Marrow Transplant 2014 20 S132 S133

68. Deniger DC Switzer K Mi T Maiti S Hurton L Singh H Huls H Olivares S Lee DA Champlin RE Cooper LJ Bispecific T-cells expressing polyclonal repertoire of endogenous gammadelta T-cell receptors and introduced CD19-specific chimeric antigen receptor Mol Ther 2013 21 638 647 23295945 10.1038/mt.2012.267 PMC3589159

69. Shimasaki N Campana D Natural killer cell reprogramming with chimeric immune receptors Methods Mol Biol 2013 969 203 220 23296936 10.1007/978-1-62703-260-5_13

70. Sangiolo D Mesiano G Carnevale-Schianca F Piacibello W Aglietta M Cignetti A Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation Expert Opin Biol Ther 2009 9 831 840 19463075 10.1517/14712590903005552

71. East JE Sun W Webb TJ Artificial antigen presenting cell (aAPC) mediated activation and expansion of natural killer T cells J Vis Exp 2012 10.3791/4333 PMC3577866 23299308

72. Papadopoulos EB Ladanyi M Emanuel D Mackinnon S Boulad F Carabasi MH Castro-Malaspina H Childs BH Gillio AP Small TN Young JW Kernan NA O'Reilly RJ Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation N Engl J Med 1994 330 1185 1191 8093146 10.1056/NEJM199404283301703

73. Walter EA Greenberg PD Gilbert MJ Finch RJ Watanabe KS Thomas ED Riddell SR Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor N Engl J Med 1995 333 1038 1044 7675046 10.1056/NEJM199510193331603

74. Rooney CM Smith CA Ng CY Loftin S Li C Krance RA Brenner MK Heslop HE Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation Lancet 1995 345 9 13 7799740 10.1016/s0140-6736(95)91150-2

75. Riddell SR Watanabe KS Goodrich JM Li CR Agha ME Greenberg PD Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones Science 1992 257 238 241 1352912 10.1126/science.1352912

76. Peggs KS Verfuerth S Pizzey A Khan N Guiver M Moss PA Mackinnon S Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines Lancet 2003 362 1375 1377 14585640 10.1016/S0140-6736(03)14634-X

77. Leen AM Christin A Myers GD Liu H Cruz CR Hanley PJ Kennedy-Nasser AA Leung KS Gee AP Krance RA Brenner MK Heslop HE Rooney CM Bollard CM Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation Blood 2009 114 4283 4292 19700662 10.1182/blood-2009-07-232454 PMC2774556

78. Leen AM Myers GD Sili U Huls MH Weiss H Leung KS Carrum G Krance RA Chang CC Molldrem JJ Gee AP Brenner MK Heslop HE Rooney CM Bollard CM Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals Nat Med 2006 12 1160 1166 16998485 10.1038/nm1475

79. Grupp SA Kalos M Barrett D Aplenc R Porter DL Rheingold SR Teachey DT Chew A Hauck B Wright JF Milone MC Levine BL June CH Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N Engl J Med 2013 368 1509 1518 23527958 10.1056/NEJMoa1215134 PMC4058440

80. Porter DL Levine BL Kalos M Bagg A June CH Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia N Engl J Med 2011 365 725 733 21830940 10.1056/NEJMoa1103849 PMC3387277

81. Rapoport AP Aqui NA Stadtmauer EA Vogl DT Fang HB Cai L Janofsky S Chew A Storek J Akpek G Badros A Yanovich S Tan MT Veloso E Pasetti MF Cross A Philip S Murphy H Bhagat R Zheng Z Milliron T Cotte J Cannon A Levine BL Vonderheide RH June CH Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma Blood 2011 117 788 797 21030558 10.1182/blood-2010-08-299396 PMC3035073

82. Hardy NM Fellowes V Rose JJ Odom J Pittaluga S Steinberg SM Blacklock-Schuver B Avila DN Memon S Kurlander RJ Khuu HM Stetler-Stevenson M Mena E Dwyer AJ Levine BL June CH Reshef R Vonderheide RH Gress RE Fowler DH Hakim FT Bishop MR Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation Blood 2012 119 2956 2959 22289893 10.1182/blood-2011-09-378398 PMC3327466

83. Rosenberg SA Yang JC Sherry RM Kammula US Hughes MS Phan GQ Citrin DE Restifo NP Robbins PF Wunderlich JR Morton KE Laurencot CM Steinberg SM White DE Dudley ME Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy Clin Cancer Res 2011 17 4550 4557 21498393 10.1158/1078-0432.CCR-11-0116 PMC3131487

84. Weber G Caruana I Rouce RH Barrett AJ Gerdemann U Leen AM Rabin KR Bollard CM Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia–implications for immunotherapy Clin Cancer Res 2013 19 5079 5091 23838315 10.1158/1078-0432.CCR-13-0955 PMC3778051

85. Mariotti S Nisini R Generation of human T cell clones Methods Mol Biol 2009 514 65 93 19048214 10.1007/978-1-60327-527-9_6

86. Okamoto S Mineno J Ikeda H Fujiwara H Yasukawa M Shiku H Kato I Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR Cancer Res 2009 69 9003 9011 19903853 10.1158/0008-5472.CAN-09-1450

87. Hacein-Bey-Abina S Garrigue A Wang GP Soulier J Lim A Morillon E Clappier E Caccavelli L Delabesse E Beldjord K Asnafi V MacIntyre E Dal Cortivo L Radford I Brousse N Sigaux F Moshous D Hauer J Borkhardt A Belohradsky BH Wintergerst U Velez MC Leiva L Sorensen R Wulffraat N Blanche S Bushman FD Fischer A Cavazzana-Calvo M Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1 J Clin Invest 2008 118 3132 3142 18688285 10.1172/JCI35700 PMC2496963

88. Scholler J Brady TL Binder-Scholl G Hwang WT Plesa G Hege KM Vogel AN Kalos M Riley JL Deeks SG Mitsuyasu RT Bernstein WB Aronson NE Levine BL Bushman FD June CH Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells Sci Transl Med 2012 4 132ra153 10.1126/scitranslmed.3003761 PMC4368443 22553251

89. Linette GP Stadtmauer EA Maus MV Rapoport AP Levine BL Emery L Litzky L Bagg A Carreno BM Cimino PJ Binder-Scholl GK Smethurst DP Gerry AB Pumphrey NJ Bennett AD Brewer JE Dukes J Harper J Tayton-Martin HK Jakobsen BK Hassan NJ Kalos M June CH Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma Blood 2013 122 863 871 23770775 10.1182/blood-2013-03-490565 PMC3743463

90. Molldrem JJ Lee PP Kant S Wieder E Jiang W Lu S Wang C Davis MM Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells J Clin Invest 2003 111 639 647 12618518 10.1172/JCI16398 PMC151894

91. Klebanoff CA Gattinoni L Restifo NP Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J Immunother 2012 35 651 660 23090074 10.1097/CJI.0b013e31827806e6 PMC3501135

92. Morgan RA Dudley ME Wunderlich JR Hughes MS Yang JC Sherry RM Royal RE Topalian SL Kammula US Restifo NP Zheng Z Nahvi A de Vries CR Rogers-Freezer LJ Mavroukakis SA Rosenberg SA Cancer regression in patients after transfer of genetically engineered lymphocytes Science 2006 314 126 129 16946036 10.1126/science.1129003 PMC2267026

93. Louis CU Savoldo B Dotti G Pule M Yvon E Myers GD Rossig C Russell HV Diouf O Liu E Liu H Wu MF Gee AP Mei Z Rooney CM Heslop HE Brenner MK Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma Blood 2011 118 6050 6056 21984804 10.1182/blood-2011-05-354449 PMC3234664

94. Gattinoni L Klebanoff CA Restifo NP Paths to stemness: building the ultimate antitumour T cell Nat Rev Cancer 2012 12 671 684 22996603 10.1038/nrc3322 PMC6352980

95. Hinrichs CS Borman ZA Cassard L Gattinoni L Spolski R Yu Z Sanchez-Perez L Muranski P Kern SJ Logun C Palmer DC Ji Y Reger RN Leonard WJ Danner RL Rosenberg SA Restifo NP Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity Proc Natl Acad Sci U S A 2009 106 17469 17474 19805141 10.1073/pnas.0907448106 PMC2762661

96. Olson JA McDonald-Hyman C Jameson SC Hamilton SE Effector-like CD8(+) T cells in the memory population mediate potent protective immunity Immunity 2013 38 1250 1260 23746652 10.1016/j.immuni.2013.05.009 PMC3703254

97. Kalos M June CH Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology Immunity 2013 39 49 60 23890063 10.1016/j.immuni.2013.07.002 PMC3809038

98. Ruella M Kalos M Adoptive immunotherapy for cancer Immunol Rev 2014 257 14 38 24329787 10.1111/imr.12136

99. Kuball J Dossett ML Wolfl M Ho WY Voss RH Fowler C Greenberg PD Facilitating matched pairing and expression of TCR chains introduced into human T cells Blood 2007 109 2331 2338 17082316 10.1182/blood-2006-05-023069 PMC1852191

100. Xue SA Gao L Thomas S Hart DP Xue JZ Gillmore R Voss RH Morris E Stauss HJ Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice Haematologica 2010 95 126 134 19679884 10.3324/haematol.2009.006486 PMC2805729

101. Stanislawski T Voss RH Lotz C Sadovnikova E Willemsen RA Kuball J Ruppert T Bolhuis RL Melief CJ Huber C Stauss HJ Theobald M Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer Nat Immunol 2001 2 962 970 11577350 10.1038/ni1001-962

102. Cohen CJ Zheng Z Bray R Zhao Y Sherman LA Rosenberg SA Morgan RA Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR J Immunol 2005 175 5799 5808 16237072 10.4049/jimmunol.175.9.5799 PMC1473968

103. Johnson LA Morgan RA Dudley ME Cassard L Yang JC Hughes MS Kammula US Royal RE Sherry RM Wunderlich JR Lee CC Restifo NP Schwarz SL Cogdill AP Bishop RJ Kim H Brewer CC Rudy SF VanWaes C Davis JL Mathur A Ripley RT Nathan DA Laurencot CM Rosenberg SA Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen Blood 2009 114 535 546 19451549 10.1182/blood-2009-03-211714 PMC2929689

104. Friedman RS Spies AG Kalos M Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific vaccine candidate Eur J Immunol 2004 34 1091 1101 15048720 10.1002/eji.200324768

105. Robbins PF Li YF El-Gamil M Zhao Y Wargo JA Zheng Z Xu H Morgan RA Feldman SA Johnson LA Bennett AD Dunn SM Mahon TM Jakobsen BK Rosenberg SA Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions J Immunol 2008 180 6116 6131 18424733 10.4049/jimmunol.180.9.6116 PMC2424230

106. Cameron BJ Gerry AB Dukes J Harper JV Kannan V Bianchi FC Grand F Brewer JE Gupta M Plesa G Bossi G Vuidepot A Powlesland AS Legg A Adams KJ Bennett AD Pumphrey NJ Williams DD Binder-Scholl G Kulikovskaya I Levine BL Riley JL Varela-Rohena A Stadtmauer EA Rapoport AP Linette GP June CH Hassan NJ Kalos M Jakobsen BK Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells Sci Transl Med 2013 5 197ra103 23926201 10.1126/scitranslmed.3006034 PMC6002776

107. Morgan RA Chinnasamy N Abate-Daga D Gros A Robbins PF Zheng Z Dudley ME Feldman SA Yang JC Sherry RM Phan GQ Hughes MS Kammula US Miller AD Hessman CJ Stewart AA Restifo NP Quezado MM Alimchandani M Rosenberg AZ Nath A Wang T Bielekova B Wuest SC Akula N McMahon FJ Wilde S Mosetter B Schendel DJ Laurencot CM Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy J Immunother 2013 36 133 151 23377668 10.1097/CJI.0b013e3182829903 PMC3581823

108. van Loenen MM de Boer R Hagedoorn RS van Egmond EH Falkenburg JH Heemskerk MH Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies Haematologica 2011 96 477 481 21109688 10.3324/haematol.2010.025916 PMC3046283

109. Reiser JB Darnault C Gregoire C Mosser T Mazza G Kearney A van der Merwe PA Fontecilla-Camps JC Housset D Malissen B CDR3 loop flexibility contributes to the degeneracy of TCR recognition Nat Immunol 2003 4 241 247 12563259 10.1038/ni891

110. Park JR Digiusto DL Slovak M Wright C Naranjo A Wagner J Meechoovet HB Bautista C Chang WC Ostberg JR Jensen MC Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma Mol Ther 2007 15 825 833 17299405 10.1038/sj.mt.6300104

111. Till BG Jensen MC Wang J Chen EY Wood BL Greisman HA Qian X James SE Raubitschek A Forman SJ Gopal AK Pagel JM Lindgren CG Greenberg PD Riddell SR Press OW Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells Blood 2008 112 2261 2271 18509084 10.1182/blood-2007-12-128843 PMC2532803

112. Kershaw MH Westwood JA Parker LL Wang G Eshhar Z Mavroukakis SA White DE Wunderlich JR Canevari S Rogers-Freezer L Chen CC Yang JC Rosenberg SA Hwu P A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer Clin Cancer Res 2006 12 6106 6115 17062687 10.1158/1078-0432.CCR-06-1183 PMC2154351

113. Lamers CH Sleijfer S van Steenbergen S van Elzakker P van Krimpen B Groot C Vulto A den Bakker M Oosterwijk E Debets R Gratama JW Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity Mol Ther 2013 21 904 912 23423337 10.1038/mt.2013.17 PMC5189272

114. Morgan RA Yang JC Kitano M Dudley ME Laurencot CM Rosenberg SA Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 Mol Ther 2010 18 843 851 20179677 10.1038/mt.2010.24 PMC2862534

115. Dao T Yan S Veomett N Pankov D Zhou L Korontsvit T Scott A Whitten J Maslak P Casey E Tan T Liu H Zakhaleva V Curcio M Doubrovina E O'Reilly RJ Liu C Scheinberg DA Targeting the intracellular WT1 oncogene product with a therapeutic human antibody Sci Transl Med 2013 5 176ra133 10.1126/scitranslmed.3005661 PMC3963696 23486779

116. Sergeeva A Alatrash G He H Ruisaard K Lu S Wygant J McIntyre BW Ma Q Li D St John L Clise-Dwyer K Molldrem JJ An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells Blood 2011 117 4262 4272 21296998 10.1182/blood-2010-07-299248 PMC3087478

117. Hinrichs CS Rosenberg SA Exploiting the curative potential of adoptive T-cell therapy for cancer Immunol Rev 2014 257 56 71 24329789 10.1111/imr.12132 PMC3920180

118. Restifo NP Dudley ME Rosenberg SA Adoptive immunotherapy for cancer: harnessing the T cell response Nat Rev Immunol 2012 12 269 281 22437939 10.1038/nri3191 PMC6292222

119. Barrett DM Singh N Porter DL Grupp SA June CH Chimeric antigen receptor therapy for cancer Annu Rev Med 2014 65 333 347 24274181 10.1146/annurev-med-060512-150254 PMC4120077

120. Kershaw MH Wang G Westwood JA Pachynski RK Tiffany HL Marincola FM Wang E Young HA Murphy PM Hwu P Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2 Hum Gene Ther 2002 13 1971 1980 12427307 10.1089/10430340260355374

121. Di Stasi A De Angelis B Rooney CM Zhang L Mahendravada A Foster AE Heslop HE Brenner MK Dotti G Savoldo B T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model Blood 2009 113 6392 6402 19377047 10.1182/blood-2009-03-209650 PMC2710932

122. Eaton D Gilham DE O'Neill A Hawkins RE Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions Gene Ther 2002 9 527 535 11948378 10.1038/sj.gt.3301685

123. Charo J Finkelstein SE Grewal N Restifo NP Robbins PF Rosenberg SA Bcl-2 overexpression enhances tumor-specific T-cell survival Cancer Res 2005 65 2001 2008 15753400 10.1158/0008-5472.CAN-04-2006 PMC2174600

124. Bollard CM Rossig C Calonge MJ Huls MH Wagner HJ Massague J Brenner MK Heslop HE Rooney CM Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity Blood 2002 99 3179 3187 11964281 10.1182/blood.v99.9.3179

125. Straathof KC Pule MA Yotnda P Dotti G Vanin EF Brenner MK Heslop HE Spencer DM Rooney CM An inducible caspase 9 safety switch for T-cell therapy Blood 2005 105 4247 4254 15728125 10.1182/blood-2004-11-4564 PMC1895037

126. Wang X Chang WC Wong CW Colcher D Sherman M Ostberg JR Forman SJ Riddell SR Jensen MC A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells Blood 2011 118 1255 1263 21653320 10.1182/blood-2011-02-337360 PMC3152493

127. Pollack SM O'Connor TP Jr Hashash J Tabbara IA Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation: a clinical review Am J Clin Oncol 2009 32 618 628 19593085 10.1097/COC.0b013e31817f9de1

128. Gooley TA Chien JW Pergam SA Hingorani S Sorror ML Boeckh M Martin PJ Sandmaier BM Marr KA Appelbaum FR Storb R McDonald GB Reduced mortality after allogeneic hematopoietic-cell transplantation N Engl J Med 2010 363 2091 2101 21105791 10.1056/NEJMoa1004383 PMC3017343

129. Wrzesinski C Paulos CM Gattinoni L Palmer DC Kaiser A Yu Z Rosenberg SA Restifo NP Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells J Clin Invest 2007 117 492 501 17273561 10.1172/JCI30414 PMC1783812

130. Gattinoni L Finkelstein SE Klebanoff CA Antony PA Palmer DC Spiess PJ Hwang LN Yu Z Wrzesinski C Heimann DM Surh CD Rosenberg SA Restifo NP Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells J Exp Med 2005 202 907 912 16203864 10.1084/jem.20050732 PMC1397916

131. Klebanoff CA Khong HT Antony PA Palmer DC Restifo NP Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy Trends Immunol 2005 26 111 117 15668127 10.1016/j.it.2004.12.003 PMC1388277

132. Dudley ME Wunderlich JR Yang JC Sherry RM Topalian SL Restifo NP Royal RE Kammula U White DE Mavroukakis SA Rogers LJ Gracia GJ Jones SA Mangiameli DP Pelletier MM Gea-Banacloche J Robinson MR Berman DM Filie AC Abati A Rosenberg SA Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma J Clin Oncol 2005 23 2346 2357 15800326 10.1200/JCO.2005.00.240 PMC1475951

133. Muranski P Boni A Wrzesinski C Citrin DE Rosenberg SA Childs R Restifo NP Increased intensity lymphodepletion and adoptive immunotherapy–how far can we go? Nat Clin Pract Oncol 2006 3 668 681 17139318 10.1038/ncponc0666 PMC1773008

134. Kalos M Levine BL Porter DL Katz S Grupp SA Bagg A June CH T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia Sci Transl Med 2011 3 95ra73 21832238 10.1126/scitranslmed.3002842 PMC3393096

135. Brentjens RJ Davila ML Riviere I Park J Wang X Cowell LG Bartido S Stefanski J Taylor C Olszewska M Borquez-Ojeda O Qu J Wasielewska T He Q Bernal Y Rijo IV Hedvat C Kobos R Curran K Steinherz P Jurcic J Rosenblat T Maslak P Frattini M Sadelain M CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia Sci Transl Med 2013 5 177ra138 10.1126/scitranslmed.3005930 PMC3742551 23515080

136. Torikai H Reik A Liu PQ Zhou Y Zhang L Maiti S Huls H Miller JC Kebriaei P Rabinovitch B Lee DA Champlin RE Bonini C Naldini L Rebar EJ Gregory PD Holmes MC Cooper LJ A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR Blood 2012 119 5697 5705 22535661 10.1182/blood-2012-01-405365 PMC3382929

137. Sullivan KM Storb R Buckner CD Fefer A Fisher L Weiden PL Witherspoon RP Appelbaum FR Banaji M Hansen J Martin P Sanders JE Singer J Thomas ED Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms N Engl J Med 1989 320 828 834 2648143 10.1056/NEJM198903303201303

138. Cruz CR Micklethwaite KP Savoldo B Ramos CA Lam S Ku S Diouf O Liu E Barrett AJ Ito S Shpall EJ Krance RA Kamble RT Carrum G Hosing CM Gee AP Mei Z Grilley BJ Heslop HE Rooney CM Brenner MK Bollard CM Dotti G Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study Blood 2013 122 2965 2973 24030379 10.1182/blood-2013-06-506741 PMC3811171

139. Terakura S Yamamoto TN Gardner RA Turtle CJ Jensen MC Riddell SR Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells Blood 2012 119 72 82 22031866 10.1182/blood-2011-07-366419 PMC3251238

140. Zhang Y Joe G Zhu J Carroll R Levine B Hexner E June C Emerson SG Dendritic cell-activated CD44hiCD8+ T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity Blood 2004 103 3970 3978 14764532 10.1182/blood-2003-09-3135

141. Dutt S Tseng D Ermann J George TI Liu YP Davis CR Fathman CG Strober S Naive and memory T cells induce different types of graft-versus-host disease J Immunol 2007 179 6547 6554 17982043 10.4049/jimmunol.179.10.6547

142. Chen BJ Deoliveira D Cui X Le NT Son J Whitesides JF Chao NJ Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse Blood 2007 109 3115 3123 17148592 10.1182/blood-2006-04-016410 PMC1852216

143. Mackinnon S Papadopoulos EB Carabasi MH Reich L Collins NH Boulad F Castro-Malaspina H Childs BH Gillio AP Kernan NA Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease Blood 1995 86 1261 1268 7632930

144. Dazzi F Szydlo RM Craddock C Cross NC Kaeda J Chase A Olavarria E van Rhee F Kanfer E Apperley JF Goldman JM Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia Blood 2000 95 67 71 10607686

145. Grupp SA Frey N Aplenc R Barrett D Chew A Kalos M Levine B Litchman M Maude S Rheingold SR Shen A Strait C Teachey D Wood PA Porter DL June C T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without GvHD In Children and Adults With Relapsed, Refractory ALL Oral Pres Am Soc Hematol 2013 122 67

146. Kochenderfer JN Dudley ME Carpenter RO Kassim SH Rose JJ Telford WG Hakim FT Halverson DC Fowler DH Hardy NM Mato AR Hickstein DD Gea-Banacloche JC Pavletic SZ Sportes C Maric I Feldman SA Hansen BG Wilder JS Blacklock-Schuver B Jena B Bishop MR Gress RE Rosenberg SA Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation Blood 2013 122 4129 4139 24055823 10.1182/blood-2013-08-519413 PMC3862276

147. De Angelis B Dotti G Quintarelli C Huye LE Zhang L Zhang M Pane F Heslop HE Brenner MK Rooney CM Savoldo B Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506) Blood 2009 114 4784 4791 19759356 10.1182/blood-2009-07-230482 PMC2786289

148. Brewin J Mancao C Straathof K Karlsson H Samarasinghe S Amrolia PJ Pule M Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease Blood 2009 114 4792 4803 19770360 10.1182/blood-2009-07-228387

149. Jonnalagadda M Brown CE Chang WC Ostberg JR Forman SJ Jensen MC Efficient selection of genetically modified human T cells using methotrexate-resistant human dihydrofolate reductase Gene Ther 2013 20 853 860 23303282 10.1038/gt.2012.97 PMC4028078

150. Yee C The use of endogenous T cells for adoptive transfer Immunol Rev 2014 257 250 263 24329802 10.1111/imr.12134

151. Baitsch L Fuertes-Marraco SA Legat A Meyer C Speiser DE The three main stumbling blocks for anticancer T cells Trends Immunol 2012 33 364 372 22445288 10.1016/j.it.2012.02.006

152. Jena B Dotti G Cooper LJ Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor Blood 2010 116 1035 1044 20439624 10.1182/blood-2010-01-043737 PMC2938125

153. Uckun FM Jaszcz W Ambrus JL Fauci AS Gajl-Peczalska K Song CW Wick MR Myers DE Waddick K Ledbetter JA Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins Blood 1988 71 13 29 3257143

154. Murphy K Travers P Walport M Janeway C Janeway's immunobiology 2012 8 New York Garland Science

155. Cooper LJ Topp MS Serrano LM Gonzalez S Chang WC Naranjo A Wright C Popplewell L Raubitschek A Forman SJ Jensen MC T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect Blood 2003 101 1637 1644 12393484 10.1182/blood-2002-07-1989

156. Brentjens RJ Latouche JB Santos E Marti F Gong MC Lyddane C King PD Larson S Weiss M Riviere I Sadelain M Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 Nat Med 2003 9 279 286 12579196 10.1038/nm827

157. Kochenderfer JN Feldman SA Zhao Y Xu H Black MA Morgan RA Wilson WH Rosenberg SA Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor J Immunother 2009 32 689 702 19561539 10.1097/CJI.0b013e3181ac6138 PMC2747302

158. Imai C Mihara K Andreansky M Nicholson IC Pui CH Geiger TL Campana D Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia Leukemia 2004 18 676 684 14961035 10.1038/sj.leu.2403302

159. Brentjens RJ Santos E Nikhamin Y Yeh R Matsushita M La Perle K Quintas-Cardama A Larson SM Sadelain M Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts Clin Cancer Res 2007 13 5426 5435 17855649 10.1158/1078-0432.CCR-07-0674

160. Cheadle EJ Hawkins RE Batha H O'Neill AL Dovedi SJ Gilham DE Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells J Immunol 2010 184 1885 1896 20089697 10.4049/jimmunol.0901440

161. Kochenderfer JN Yu Z Frasheri D Restifo NP Rosenberg SA Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells Blood 2010 116 3875 3886 20631379 10.1182/blood-2010-01-265041 PMC2981541

162. Milone MC Fish JD Carpenito C Carroll RG Binder GK Teachey D Samanta M Lakhal M Gloss B Danet-Desnoyers G Campana D Riley JL Grupp SA June CH Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo Mol Ther 2009 17 1453 1464 19384291 10.1038/mt.2009.83 PMC2805264

163. Carpenito C Milone MC Hassan R Simonet JC Lakhal M Suhoski MM Varela-Rohena A Haines KM Heitjan DF Albelda SM Carroll RG Riley JL Pastan I June CH Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains Proc Natl Acad Sci U S A 2009 106 3360 3365 19211796 10.1073/pnas.0813101106 PMC2651342

164. Davila ML Kloss CC Gunset G Sadelain M CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia PLoS One 2013 8 e61338 23585892 10.1371/journal.pone.0061338 PMC3621858

165. Kochenderfer JN Wilson WH Janik JE Dudley ME Stetler-Stevenson M Feldman SA Maric I Raffeld M Nathan DA Lanier BJ Morgan RA Rosenberg SA Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 Blood 2010 116 4099 4102 20668228 10.1182/blood-2010-04-281931 PMC2993617

166. Kochenderfer JN Dudley ME Feldman SA Wilson WH Spaner DE Maric I Stetler-Stevenson M Phan GQ Hughes MS Sherry RM Yang JC Kammula US Devillier L Carpenter R Nathan DA Morgan RA Laurencot C Rosenberg SA B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells Blood 2012 119 2709 2720 22160384 10.1182/blood-2011-10-384388 PMC3327450

167. Porter DL Kalos M Frey N Grupp SA Loren A Jemison C Gilmore J McConville H Capobianchi J Lledo L Chew A Zheng Z Levine B June C Chimeric antigen receptor modified T cells directed against CD19 (CTL019 cells) have long-term persistence and induce durable responses in relapsed, refractory CLL Poster Pres Am Soc Hematol 2013 122 4162

168. Cardoso AA Schultze JL Boussiotis VA Freeman GJ Seamon MJ Laszlo S Billet A Sallan SE Gribben JG Nadler LM Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen Blood 1996 88 41 48 8704200

169. Kebelmann-Betzing C Korner G Badiali L Buchwald D Moricke A Korte A Kochling J Wu S Kappelmeier D Oettel K Henze G Seeger K Characterization of cytokine, growth factor receptor, costimulatory and adhesion molecule expression patterns of bone marrow blasts in relapsed childhood B cell precursor all Cytokine 2001 13 39 50 11145841 10.1006/cyto.2000.0794

170. Davila ML Riviere I Wang X Bartido S Park J Curran K Chung SS Stefanski J Borquez-Ojeda O Olszewska M Qu J Wasielewska T He Q Fink M Shinglot H Youssif M Satter M Wang Y Hosey J Quintanilla H Halton E Bernal Y Bouhassira DC Arcila ME Gonen M Roboz GJ Maslak P Douer D Frattini MG Giralt S Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia Science translational medicine 2014 6 224ra225 10.1126/scitranslmed.3008226 PMC4684949 24553386

171. Frey NV Porter DL Graft-versus-host disease after donor leukocyte infusions: presentation and management Best Pract Res Clin Haematol 2008 21 205 222 18503987 10.1016/j.beha.2008.02.007 PMC2504712

172. Hosen N Sonoda Y Oji Y Kimura T Minamiguchi H Tamaki H Kawakami M Asada M Kanato K Motomura M Murakami M Fujioka T Masuda T Kim EH Tsuboi A Oka Y Soma T Ogawa H Sugiyama H Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells Br J Haematol 2002 116 409 420 11841446 10.1046/j.1365-2141.2002.03261.x

173. Scharnhorst V van der Eb AJ Jochemsen AG WT1 proteins: functions in growth and differentiation Gene 2001 273 141 161 11595161 10.1016/s0378-1119(01)00593-5

174. Yang L Han Y Suarez Saiz F Minden MD A tumor suppressor and oncogene: the WT1 story Leukemia 2007 21 868 876 17361230 10.1038/sj.leu.2404624

175. Miwa H Beran M Saunders GF Expression of the Wilms' tumor gene (WT1) in human leukemias Leukemia 1992 6 405 409 1317488

176. Miyoshi Y Ando A Egawa C Taguchi T Tamaki Y Tamaki H Sugiyama H Noguchi S High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients Clin Cancer Res 2002 8 1167 1171 12006533

177. Dupont J Wang X Marshall DS Leitao M Hedvat CV Hummer A Thaler H O'Reilly RJ Soslow RA Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray Gynecol Oncol 2004 94 449 455 15297187 10.1016/j.ygyno.2004.05.014

178. Oji Y Miyoshi S Maeda H Hayashi S Tamaki H Nakatsuka S Yao M Takahashi E Nakano Y Hirabayashi H Shintani Y Oka Y Tsuboi A Hosen N Asada M Fujioka T Murakami M Kanato K Motomura M Kim EH Kawakami M Ikegame K Ogawa H Aozasa K Kawase I Sugiyama H Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers Int J Cancer 2002 100 297 303 12115544 10.1002/ijc.10476

179. Campbell CE Kuriyan NP Rackley RR Caulfield MJ Tubbs R Finke J Williams BR Constitutive expression of the Wilms tumor suppressor gene (WT1) in renal cell carcinoma Int J Cancer 1998 78 182 188 9754650 10.1002/(sici)1097-0215(19981005)78:2<182::aid-ijc11>3.0.co;2-d

180. Bergmann L Miething C Maurer U Brieger J Karakas T Weidmann E Hoelzer D High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome Blood 1997 90 1217 1225 9242555

181. Ostergaard M Olesen LH Hasle H Kjeldsen E Hokland P WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study Br J Haematol 2004 125 590 600 15147374 10.1111/j.1365-2141.2004.04952.x

182. Ogawa H Tamaki H Ikegame K Soma T Kawakami M Tsuboi A Kim EH Hosen N Murakami M Fujioka T Masuda T Taniguchi Y Nishida S Oji Y Oka Y Sugiyama H The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia Blood 2003 101 1698 1704 12406915 10.1182/blood-2002-06-1831

183. Hamalainen MM Kairisto V Juvonen V Johansson J Auren J Kohonen K Remes K Salmi TT Helenius H Pelliniemi TT Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia Eur J Haematol 2008 80 201 207 18081724 10.1111/j.1600-0609.2007.01009.x

184. Yamagami T Sugiyama H Inoue K Ogawa H Tatekawa T Hirata M Kudoh T Akiyama T Murakami A Maekawa T Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis Blood 1996 87 2878 2884 8639907

185. O'Reilly RJ Dao T Koehne G Scheinberg D Doubrovina E Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation Semin Immunol 2010 22 162 172 20537908 10.1016/j.smim.2010.02.003 PMC4183056

186. May RJ Dao T Pinilla-Ibarz J Korontsvit T Zakhaleva V Zhang RH Maslak P Scheinberg DA Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells Clin Cancer Res 2007 13 4547 4555 17671141 10.1158/1078-0432.CCR-07-0708

187. Oka Y Elisseeva OA Tsuboi A Ogawa H Tamaki H Li H Oji Y Kim EH Soma T Asada M Ueda K Maruya E Saji H Kishimoto T Udaka K Sugiyama H Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms’ tumor gene (WT1) product Immunogenetics 2000 51 99 107 10663572 10.1007/s002510050018

188. Weber G Karbach J Kuci S Kreyenberg H Willasch A Koscielniak E Tonn T Klingebiel T Wels WS Jager E Bader P WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation Leukemia 2009 23 1634 1642 19357702 10.1038/leu.2009.70

189. Ohminami H Yasukawa M Fujita S HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide Blood 2000 95 286 293 10607714

190. Doubrovina ES Doubrovin MM Lee S Shieh JH Heller G Pamer E O'Reilly RJ In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity Clin Cancer Res 2004 10 7207 7219 15534094 10.1158/1078-0432.CCR-04-1040

191. Scheibenbogen C Letsch A Thiel E Schmittel A Mailaender V Baerwolf S Nagorsen D Keilholz U CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia Blood 2002 100 2132 2137 12200377 10.1182/blood-2002-01-0163

192. Rezvani K Brenchley JM Price DA Kilical Y Gostick E Sewell AK Li J Mielke S Douek DC Barrett AJ T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization Clin Cancer Res 2005 11 8799 8807 16361568 10.1158/1078-0432.CCR-05-1314

193. Gao L Bellantuono I Elsasser A Marley SB Gordon MY Goldman JM Stauss HJ Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1 Blood 2000 95 2198 2203 10733485

194. Doubrovina E Carpenter T Pankov D Selvakumar A Hasan A O'Reilly RJ Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias Blood 2012 120 1633 1646 22623625 10.1182/blood-2011-11-394619 PMC3429306

195. Kim YS Yuan M Itzkowitz SH Sun QB Kaizu T Palekar A Trump BF Hakomori S Expression of LeY and extended LeY blood group-related antigens in human malignant, premalignant, and nonmalignant colonic tissues Cancer Res 1986 46 5985 5992 2428490

196. Kobayashi K Sakamoto J Kito T Yamamura Y Koshikawa T Fujita M Watanabe T Nakazato H Lewis blood group-related antigen expression in normal gastric epithelium, intestinal metaplasia, gastric adenoma, and gastric carcinoma Am J Gastroenterol 1993 88 919 924 8503388

197. Dettke M Loibner H Different types of FCgamma-receptors are involved in anti-Lewis Y antibody induced effector functions in vitro Br J Cancer 2000 82 441 445 10646902 10.1054/bjoc.1999.0940 PMC2363301

198. Westwood JA Smyth MJ Teng MW Moeller M Trapani JA Scott AM Smyth FE Cartwright GA Power BE Honemann D Prince HM Darcy PK Kershaw MH Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice Proc Natl Acad Sci U S A 2005 102 19051 19056 16365285 10.1073/pnas.0504312102 PMC1323148

199. Sakamoto J Furukawa K Cordon-Cardo C Yin BW Rettig WJ Oettgen HF Old LJ Lloyd KO Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines Cancer Res 1986 46 1553 1561 3510728

200. Peinert S Prince HM Guru PM Kershaw MH Smyth MJ Trapani JA Gambell P Harrison S Scott AM Smyth FE Darcy PK Tainton K Neeson P Ritchie DS Honemann D Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen Gene Ther 2010 17 678 686 20200563 10.1038/gt.2010.21

201. Miyake M Taki T Hitomi S Hakomori S Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung N Engl J Med 1992 327 14 18 1317941 10.1056/NEJM199207023270103

202. Kitamura K Stockert E Garin-Chesa P Welt S Lloyd KO Armour KL Wallace TP Harris WJ Carr FJ Old LJ Specificity analysis of blood group Lewis-y (Le(y)) antibodies generatedagainst synthetic and natural Le(y) determinants Proc Natl Acad Sci U S A 1994 91 12957 12961 7809154 10.1073/pnas.91.26.12957 PMC45559

203. Scott AM Tebbutt N Lee FT Cavicchiolo T Liu Z Gill S Poon AM Hopkins W Smyth FE Murone C MacGregor D Papenfuss AT Chappell B Saunder TH Brechbiel MW Davis ID Murphy R Chong G Hoffman EW Old LJ A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen Clin Cancer Res 2007 13 3286 3292 17545534 10.1158/1078-0432.CCR-07-0284

204. Saleh MN Sugarman S Murray J Ostroff JB Healey D Jones D Daniel CR LeBherz D Brewer H Onetto N LoBuglio AF Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors J Clin Oncol 2000 18 2282 2292 10829049 10.1200/JCO.2000.18.11.2282

205. Herbertson RA Tebbutt NC Lee FT MacFarlane DJ Chappell B Micallef N Lee ST Saunder T Hopkins W Smyth FE Wyld DK Bellen J Sonnichsen DS Brechbiel MW Murone C Scott AM Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers Clin Cancer Res 2009 15 6709 6715 19825951 10.1158/1078-0432.CCR-09-0536 PMC6944432

206. Vera J Savoldo B Vigouroux S Biagi E Pule M Rossig C Wu J Heslop HE Rooney CM Brenner MK Dotti G T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells Blood 2006 108 3890 3897 16926291 10.1182/blood-2006-04-017061 PMC1895462

207. Pricop L Hatakeyama A Isobe H Bona C Analysis of lambda repertoire in kappa-deficient mice Clin Immunol Immunopathol 1995 76 S179 S187 7554465 10.1016/s0090-1229(95)90162-0

208. Zegers BJ Maertzdorf WJ Van Loghem E Mul NA Stoop JW Van Der Laag J Vossen JJ Ballieux RE Kappa-chain deficiency. An immunoglobulin disorder N Engl J Med 1976 294 1026 1030 815819 10.1056/NEJM197605062941902

209. Pule MA Straathof KC Dotti G Heslop HE Rooney CM Brenner MK A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells Mol Ther 2005 12 933 941 15979412 10.1016/j.ymthe.2005.04.016

210. Ocqueteau M San Miguel JF Gonzalez M Almeida J Orfao A Do myelomatous plasma cells really express surface immunoglobulins? Haematologica 1996 81 460 463 8952161

211. Matutes E Owusu-Ankomah K Morilla R Garcia Marco J Houlihan A Que TH Catovsky D The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL Leukemia 1994 8 1640 1645 7523797

212. Matsushita H Nakamura N Tanaka Y Ohgiya D Tanaka Y Damdinsuren A Asai S Yabe M Kawada H Ogawa Y Ando K Miyachi H Clinical and pathological features of B-cell non-Hodgkin lymphomas lacking the surface expression of immunoglobulin light chains Clin Chem Lab Med 2012 50 1665 1670 23100378 10.1515/cclm-2011-1854

213. Warren EH Zhang XC Li S Fan W Storer BE Chien JW Boeckh MJ Zhao LP Martin PJ Hansen JA Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT Blood 2012 120 2796 2806 22859606 10.1182/blood-2012-04-347286 PMC3466963

214. Fontaine P Roy-Proulx G Knafo L Baron C Roy DC Perreault C Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease Nat Med 2001 7 789 794 11433342 10.1038/89907

215. Warren EH Fujii N Akatsuka Y Chaney CN Mito JK Loeb KR Gooley TA Brown ML Koo KK Rosinski KV Ogawa S Matsubara A Appelbaum FR Riddell SR Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens Blood 2010 115 3869 3878 20071660 10.1182/blood-2009-10-248997 PMC2869557

216. Nilsson K Klein G Henle W Henle G The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV Int J Cancer 1971 8 443 450 4332899 10.1002/ijc.2910080312

217. Fisher B Packard BS Read EJ Carrasquillo JA Carter CS Topalian SL Yang JC Yolles P Larson SM Rosenberg SA Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma J Clin Oncol 1989 7 250 261 2644399 10.1200/JCO.1989.7.2.250

218. Kamei M Nannya Y Torikai H Kawase T Taura K Inamoto Y Takahashi T Yazaki M Morishima S Tsujimura K Miyamura K Ito T Togari H Riddell SR Kodera Y Morishima Y Takahashi T Kuzushima K Ogawa S Akatsuka Y HapMap scanning of novel human minor histocompatibility antigens Blood 2009 113 5041 5048 18809759 10.1182/blood-2008-07-171678 PMC3654783

219. den Haan JM Meadows LM Wang W Pool J Blokland E Bishop TL Reinhardus C Shabanowitz J Offringa R Hunt DF Engelhard VH Goulmy E The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism Science 1998 279 1054 1057 9461441 10.1126/science.279.5353.1054

220. Bocchia M Gentili S Abruzzese E Fanelli A Iuliano F Tabilio A Amabile M Forconi F Gozzetti A Raspadori D Amadori S Lauria F Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial Lancet 2005 365 657 662 15721470 10.1016/S0140-6736(05)17945-8

221. Falkenburg JH Wafelman AR Joosten P Smit WM van Bergen CA Bongaerts R Lurvink E van der Hoorn M Kluck P Landegent JE Kluin-Nelemans HC Fibbe WE Willemze R Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes Blood 1999 94 1201 1208 10438707

222. Dubrovsky L Pankov D Brea EJ Dao T Scott A Yan S O’Reilly RJ Liu C Scheinberg DA A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias Blood 2014 123 3296 3304 24723681 10.1182/blood-2014-01-549022 PMC4046427

223. Giordano Attianese GM Marin V Hoyos V Savoldo B Pizzitola I Tettamanti S Agostoni V Parma M Ponzoni M Bertilaccio MT Ghia P Biondi A Dotti G Biagi E In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor Blood 2011 117 4736 4745 21406718 10.1182/blood-2010-10-311845 PMC3100686

224. Mardiros A Dos Santos C McDonald T Brown CE Wang X Budde LE Hoffman L Aguilar B Chang WC Bretzlaff W Chang B Jonnalagadda M Starr R Ostberg JR Jensen MC Bhatia R Forman SJ T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia Blood 2013 122 3138 3148 24030378 10.1182/blood-2012-12-474056 PMC3814731

225. Nagai K Ochi T Fujiwara H An J Shirakata T Mineno J Kuzushima K Shiku H Melenhorst JJ Gostick E Price DA Ishii E Yasukawa M Aurora kinase A-specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity Blood 2012 119 368 376 22025529 10.1182/blood-2011-06-360354